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Summary	  
 
Colorectal cancer is one of the leading cause of mortality in USA and worldwide. 
Colon cancer is a complex world of connective tissue epithelial, inflammatory and 
endothelial cell interactions. It s long known that patients with persistent colitis 
are at high risk of developing colon cancer, where the patients passes through a 
phase from colitis to colitis induced dysplasia and finally invasive cancer. Though 
a lot of efforts have been poured into understanding the mechanisms underlying 
the etiology of colon cancer, less has been known with respect to the changes 
happening at genomic and proteomic levels in the inflammatory compartment of 
the colon cancer with respect to interaction with the tumor epithelium and 
subsequent tumor progression.   
It is well known that the levels of PI3K/AKT and inflammatory cells mainly mast 
cells and macrophages are upregulated in the cancer. However, few efforts have 
been done to understand the pathogenesis in this direction, but they lacked in the 
correlative study of PI3K/AKT or immune infiltration in colon cancer or colitis and 
their spatial distribution with respect to cancer prognosis. Hence for the first time 
in this study a novel investigation was conducted where human patients were 
studied in the various stages of inflammation associated colonic illness i.e. colitis 
to dysplasia and invasive cancer and compared it to normal amongst 
themselves. The human-patient colonic tissue specimens were investigated for 
the spatial distribution of mast cells, macrophages and pAKT in the histological 
areas of musoca and submucosa. It was observed that mast cells, macrophages 
and pAKT levels incrementally rise from colitis to dysplasia to cancer in the 
submucosal tissues. In mucosal tissue, pAKT levels were found atleast 10 fold 
higher in the stromal cells in comparison with epithelial cells. The stromal and 
submucosal pAKT+ cells were found to be the macrophages that progressively 
infiltrate from colitis to dysplasia and invasive cancer, also mast cells were found 
to be high in pAKT activity.  
To investigate the role of PI3K/AKT in mast cells and macrophages biology and 
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their crosstalk with colonic epithelium a pan PI3K/AKT inhibitor used in clinical 
trials “LY2949002” was used. PI3K/AKT in mast cells was found to be critical for 
peripheral blood isolated human macrophage migration. LY294002 treatment of 
human and gut-derived murine mast cells restricted their ability to degranulate in 
dose-dependent manner. Moreover, inhibition of PI3K/AKT in human and mouse 
mast cells blocked the release of growth factors from them, and attenuated tumor 
proliferation and invasion promoting properties of mast cells. Also, PI3K/AKT 
inhibition in tumor infiltrating leukocytes isolated from colitis-associated patients 
lowered their soluble growth factor and cell-cell contact based tumor invasion 
promoting properties.  
Treatment of LY294002 using intra-peritoneal injections lowered the incidence of 
colitis associated invasive cancer development by day 56 in the Piroxicam 
treated IL-10-/- mice. LY294002 displayed a striking effect on the epithelial 
proliferation, induced tumor apoptosis and attenuated the pAKT levels. 
LY294002 showed special predilection for the pAKT+ stromal cells in comparison 
with pAKT+ epithelial cells. Moreover, frequencies of mast cells and granulocyte-
based inflammation were lowered after LY294002 treatment. Finally, the in situ 
degraunulating potential of mast cells was attenuated by LY294002 treatment. 
In conclusion, using in situ human patient specimen study, in vitro human and 
murine assays and in vivo mouse model system this study confirms the role of 
PI3K/AKT pathway in mast cells and tumor infiltrating leukocytes in crosstalk with 
the colonic epithelium and progression of colonic tissue from colitis.  
5	   	  
Zusammenfassung	  
 
Das kolorektale Karzinom ist eines der häufigsten Todesarten weltweit. Das 
Kolonkarzinom ist eine komplexe Krankheit aus konvektivem epithelialem 
Gewebe, Entzündungen und endothelialen Zellinteraktionen. Es ist bekannt, 
dass Patienten mit persistenter Kolitis ein höheres Risiko haben Darmkrebs zu 
entwickeln. Diese Patienten gehen durch verschiedene Stadien der Kolitis. Diese 
entwickeln sich über eine Kolitis, welche die Dysplasie induziert und danach 
gehen diese zu invasiven Karzinome über. Obwohl viele Arbeitsgruppen zum 
Verständnis des Mechanismus der Ätiologie des Kolonkarzinoms beitragen, ist 
bis zum heutigen Zeitpunkt immer noch sehr wenig über die Veränderungen in 
der Genetik und die Proteomik bekannt. Dies gilt vor allem in den entzündlichen 
Teilen des Kolonkarzinoms in Bezug auf die Interaktion mit dem Tumorepithelium 
und der nachfolgenden Tumorprogession. 
Es ist bekannt, dass PI3K/AKT und entzündlichen Zellen, welche hauptsächlich 
Mastzellen und Makrophagen sind, im Karzinom erhöht sind. Jedoch ist bis zum 
heutigen Zeitpunkt sehr wenig zum Verständnis der Pathogenese in diesem 
spezifischem Feld beigetragen worden. Bis zum jetzigen Zeitpunkt sind noch 
keine korrelativen Experimente von PI3K/AKT und der immunen Infiltration im 
Kolonkarzinom, oder bei Kolitis und deren räumlichen Verteilung in der 
Karzinom-Prognose durchgeführt wurden. In dieser Arbeit wurden in den 
Patienten die verschiedenen Phasen der Entzündung, die mit Kolitis assoziiert 
sind, die danach zur Dysplasie übergehen und zum Schluss in invasiven 
Karzinom endet, untersucht und mit normalen Gewebe verglichen. Die 
Patientenproben aus dem Darmgewebe wurden auf die räumliche Verteilung der 
Mastzellen, Makrophagen und dem pAKT Level in der Mukosa und Submukosa 
histologisch untersucht. Es konnte gezeigt werden, dass Mastzellen, 
Makrophagen und das pAKT Level schrittweise in der Kolitis über zur Dysplasie 
bis hin zum Karzinom im submukosalem Gewebe ansteigen. Im mukosalem 
Gewebe konnte ein über 10-facher Anstieg des pAKT Levels in den Stromazellen 
beobachtet werden im Vergleich zu dem Epithelzellen. Die Stroma- und 
submukosalen pAKT positiven Zellen wurden als Makrophagen identifiziert, 
welche schrittweise von der Kolitis über Dysplasie bis hin zum invasiven 
Karzinom infiltrieren. Des Weiteren wurde auch in den Mastzellen eine hohe 
pAKT Aktivität festgestellt. 
Um die Rolle von PI3K/AKT in Mastzellen und Makrophagen in Bezug auf deren 
Biologie und Wechselwirkung mit dem Kolonepithel zu untersuchen wurde der 
PI3K/AKT Inhibitor LY294002 verwendet, welcher auch in klinischen Trials zum 
Einsatz kommt. Das in Mastzellen gefundene PI3K/AKT wirkt sich kritisch auf die 
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humane Makrophagen Migration aus, die aus peripheren Blut isoliert wurden. Die 
Behandlung mit LY294002 in humanen und murinen Darm-Mastzellen 
beschränkt deren Eigenschaften zu degranulieren in einer dosisabhängigen 
Weise. Darüber hinaus blockiert die Inhibition von PI3K/AKT in humanen und 
murinen Mastzellen die Freisetzung von Wachstumsfaktoren und verringert die 
Tumorproliferation und die fördernden Eigenschaften zur Invasion. Außerdem 
verringert die Inhibition von PI3K/AKT die in Tumoren infiltrierenden Leukozyten, 
isoliert aus Kolitis-assoziierten Patienten, deren löslichen Wachstumsfaktoren 
und Zell-Zell-Kontakte basierend an deren fördernden Eigenschaften zur 
Tumorinvasion. 
Die Behandlung mit LY294002 durch intraperitonealen Injektionen verringert die 
Kolitis Inzidenz assoziiert mit der Entwicklung von invasiven Karzinomen ab dem 
56. Tag in IL-10-/- Mäusen, die mit Piroxicam behandelt wurden. LY294002 zeigte 
eine signifikanten Einfluss auf die epitheliale Proliferation, die Tumorinduzierte 
Apoptose und die Abnahme von pAKT. Darüber hinaus zeigte LY294002 eine 
spezielle Präferenz für die pAKT positiven Stromazellen im Vergleich mit den 
pAKT positiven Epithelzellen. Des Weiteren wurden die Frequenzen von 
Mastzellen und Granulozyten-basierende Entzündungen nach LY294002 
Behandlung verringert. Schließlich wurde das in-situ degranulierende Potential 
der Mastzellen verringert. 
Zusammenfassend bestätigt diese Arbeit die Rolle des PI3K/AKT Signalweg in 
Mastzellen und Tumor infiltrierende Leukozyten in der gegenseitigen 
Beeinflussung des Koloneptheliums und die Progression des Kolongewebes von 
Kolitis über zum invasiven Karzinoms. 	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Abbreviations	  and	  definitions 
 
%  Percentage 
[3H]   Tritium, hydrogen-3 
µg  Microgram 
ul  Microlitre 
µm  Micrometer 
µM  Micromolar 
ATCC  American Type Culture Collection 
BMMCs Bone marrow derived murine mast cells 
BRDU  Bromodeoxyuridine  
BSA  Bovine Serum Albumin 
CAC  Colitis associated cancer 
CAE  Chloroacetate esterase  
CFSE  Carboxyfluorescein succinimidyl ester 
CM  Conditioned medium 
CPM  Counts per minute 
CRC  Colorectal Cancer  
CSF  Colony-stimulating factor 
CSF1R  Colony-stimulating factor 1 receptor 
DAPI  4',6-diamidino-2-phenylindole 
DEN  Diethylnitroseamine 
DMEM Dulbecco’s modified Eagle's medium 
DMSO  Dimethyl sulfoxide 
DNP  2,4-Dinitrophenol  
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DSS  Dextran sulfate sodium 
EHS   Engelbreth-Holm-Swarm  
et al.   Latin “et alii”, - “and others” 
FACS  Fluorescence activated cell sorter/ flow cytometry 
FAP  Familial adenomatous polyposis 
FBS  Fetal bovine serum 
GPCRs G protein-coupled receptors  
GMMCs Gut derived murine mast cells  
H&E  Hematoxylin and Eosin  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HMGB1 High mobility group box protein 1  
M  Molar 
MC    Mast cell 
MCP  Mast cell progenitors 
mg  Milligram 
ml  Milliliter  
mM  Millimolar 
MMP  Matrix metalloprotease 
ng  Nanogram 
NSAIDs Non-steroidal anti-inflammatory drugs 
pAKT  Phosphorylated AKT 
pAKT-T308   Phosphorylated AKT at Threonine 308 residue 
pAKT-S473   Phosphorylated AKT at Serine 473 residue 
PDGF  Platelet-derived growth factor 
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PB   Peripheral blood 
PBMC  Peripheral Blood mononuclear cells 
PBS   Phosphate buffered saline 
PI3K   Phosphoinositol 3-Kinase 
PI3Kγ  Phosphoinositide 3-kinase-γ  
PNAG  4-nitrophenyl N- acetyl-β-D-glucosaminide  
rpm   Rounds per minute 
RPMI  Roswell Park Memorial Institute medium 
RTKs   Receptor tyrosine kinases  
SAA3  Serumamyloid A3  
SCF  Stem cell factor 
TAMs  Tumor-Associated Macrophages 
TGF  Transforming growth factor 
TILs  Tumor Infiltrating Leukocytes 
TLR/IL1Rs Toll-like/ IL-1 receptors  
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling  
U  Units 
UC  Ulcerative Colitis 
VEGF  Vascular endothelial growth factor 
X  Times 
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1.	  Introduction	  
1.1 Basics of cancer development 
Cancer is the outcome of outgrowth of a clonal population of transformed cells 
from tissue(Hanahan & Weinberg, 2000). Carcinogenesis is a process of cancer 
development that could be modeled and characterized in various ways. One way 
to describe this process is to characterize the essential features of both cancer 
cells and tumors called as the “hallmarks” of cancer(Hanahan & Weinberg, 
2000). Carcinogenesis requires the acquisition of six fundamental properties: 
insensitivity to anti-proliferative, signals, self-sufficient proliferation, unlimited 
replicative potential, evasion of apoptosis, persistent vascularization, and tissue 
invasion and metastasis needed for malignancy (Figure 1)(Hanahan & 
Weinberg, 2000). 
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Figure 1. Immunosurveillance, inflammation and mechanism of 
colorectal cancer progression (CRC) and effector functions of CRC. 
[Modified and adapted from(Terzic et al, 2010)] 
In another way carcinogenesis can be described with regard to a step-wise 
development, functionally grouped into three phases: initiation, promotion, and 
progression (Kinzler & Vogelstein, 1996). Initiation is a process characterized by 
genomic changes within the “cancer cell,” like gene deletion, point mutations, 
amplification and chromosomal rearrangements that lead to irreversible cellular 
changes(Kinzler & Vogelstein, 1996). Further tumor development is dependent 
on survival and clonal expansion of these “initiated” cells. Progression of cancer 
encompasses a substantial growth in size and either growth-related or mutually 
exclusive metastasis(Kinzler & Vogelstein, 1996). 
Accumulation of genetic lesions in cells is an essential step in the development of 
the cancer. These events eventhough are required for initiation but may also play 
a role in the promotion or progression of tumor development (Kinzler & 
Vogelstein, 1996). These genomic events include the inactivation of tumor 
suppressor genes or/and activation of cellular proto-oncogenes that act in a 
“cancer-cell intrinsic” manner bestowing these cells with neoplastic 
properties(Terzic et al, 2010). However, eventhough these cell autonomous 
properties are required for tumorigenesis, they are not sufficient. Scientific 
studies over the last two decades have ratified the concept that carcinogenesis 
and malignancy is the result of processes involving both the cancer cells 
themselves and non-cancer cells(Terzic et al, 2010). A clear example of this is 
reported by the requirement of neo-angiogenesis for tumor growth and 
progression, and thus the contribution of the vascular endothelial cells is 
vital(Folkman, 2002).  
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1.2 Colorectal cancer (CRC) 
Every year more than 1 million new cases of colorectal cancer (CRC) are 
diagnosed worldwide each year(Tenesa & Dunlop, 2009). Globally CRC is the 3rd 
most common malignancy and 4th most common cause of cancer 
mortality(Tenesa & Dunlop, 2009). Despite important advances in detection, 
surgery and chemotherapy CRC is the 2nd most common cause of cancer deaths 
in the United States and other developed countries(Jemal et al, 2009; Jemal et 
al, 2008). Colorectal cancer is caused by mutations that drive epithelial 
transformation through series of steps starting with pre-neoplasia to an 
intermediary dysplastic stage and finally invasive cancer (Muto et al, 1975; 
Powell et al, 1992). While inactivation of tumor suppressor genes and oncogenic 
mutations are necessary they are not sufficient for cancer progression (Kinzler & 
Vogelstein, 1998). However, only about 20% of CRC cases have a familial basis 
(Rustgi, 2007); some are associated with well-defined syndromes, such as 
familial adenomatous polyposis and hereditary non-polyposis colorectal cancer. 
Surprisingly, the largest fraction of CRC cases has been linked to environmental 
etiology rather than heritable genetic changes (Rustgi, 2007). Risk factors 
include specific intestinal commensals and pathogens, environmental and food-
borne mutagens and chronic intestinal inflammation that precede tumor 
development(Rustgi, 2007). 
1.2.1 Colitis-associated cancer (CAC) and colorectal cancer (CRC) 
Colitis-associated cancer (CAC) is an inflammatory bowel disease (IBD) 
associated CRC subtype, has high mortality, and is difficult to treat(Feagins et al, 
2009). Within 30 years of the onset of IBD more than 20% of IBD patients 
develop CAC, and more than 50% of them die from CAC(Lakatos & Lakatos, 
2008). Inspite of immune-mediated mechanistic link between IBD and 
CAC(Atreya & Neurath, 2008; Greten et al, 2004), CAC shares lot of similarities 
with other types of CRC that develop without any signs of persistent inflammatory 
disease. Non-inflammatory CRC and CAC both share some of the essential 
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stages of carcinogenesis that includes formation of aberrant crypt foci, dysplasia, 
adenomas, polyps, and carcinomas(Terzic et al, 2010). However, for CAC 
somewhat different pathogenic sequences have been proposed. The sequences 
include injury-dysplasia, carcinoma and chronic inflammation that arise without 
the formation of well-defined adenoma. Nonetheless, Wnt, β-catenin, K-ras, p53, 
transforming growth factor (TGF)-β, and the DNA mismatch repair (MMR) 
proteins, are common genetic and signaling pathways that are altered in sporadic 
CRC and CAC(Terzic et al, 2010), however the time points at which inactivation 
of p53 and Adenomatous Polyposis Coli (APC) and activation of K-Ras takes 
place can differ between CRC and CAC(Lakatos & Lakatos, 2008; Sheng et al, 
1998). Moreover, it has been reported in animal models that carcinogenesis in 
sporadic CRC and CAC is equally influenced by the gut microflora(Khazaie et al, 
2012; Terzic et al, 2010). Intriguingly, even colorectal tumors that are not 
associated with clinically detectable Inflammatory bowel disease (IBD) develop 
robust inflammatory cell infiltration and pronounced expression of 
proinflammatory cytokines(Atreya et al, 2008; Atreya & Neurath, 2008; Clevers, 
2004; Waldner & Neurath, 2008). 
1.2.2 Cancer and inflammation 
A link between the development of cancer and inflammation has been known for 
long(Balkwill & Mantovani, 2001; Coussens & Werb, 2002). Observing 
inflammation including leukocyte infiltration at tumors infected with microbes or at 
sites of chronic irritation is well known(Khazaie et al, 2012; Rakoff-Nahoum, 
2006). However Virchow in 1863 first time reported the presence of leukocytes in 
cancer and the link of inflammation to cancer. Further evidence for the role of 
inflammation has come from the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) in the prevention of spontaneous tumor formation in people with 
familial adenomatous polyposis (FAP)(Ulrich et al, 2006). Also, wound repair or 
inflammatory gene expression often correlate negatively with cancer stage and 
prognosis(Chang et al, 2004; Galon et al, 2006; Wang et al, 2006). Thus, 
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inflammation and cancer are linked by epidemiology, histopathology, 
inflammatory profiles, and the efficacy of anti-inflammatory drugs in prophylaxis.  
Interestingly, several reports suggest that inflammatory and immune systems 
may inhibit the development of cancer (Figure 1). In tumor immunosurveillance, 
the host may develop a mechanism to perceive and eliminate transformed 
cells(Rakoff-Nahoum, 2006). Also, adaptive immune recognition of tumor-
associated and specific antigens may be an important means by which the 
immune system controls the development of cancer(Smyth et al, 2006). 
However, it seems that the net effect of the inflammation is to positively affect 
tumor development. The relationship between cancer and inflammation is 
complex and cannot be reduced to one grand theory.  
1.3 Inflammation can cause cancer 
It is well established that long-standing inflammation secondary to chronic 
infection or irritation predisposes to cancer(Cheon et al, 2011; Gounaris et al, 
2009; Gounaris et al, 2007; Gounaris et al, 2008; Khazaie et al, 2011; Strouch et 
al, 2010). The chronic inflammation associated with infection and irritation may 
lead to environments that foster genomic lesions and tumor initiation. One 
effector mechanism by which the host resists microbial infection is the production 
of free radicals such as reactive oxygen intermediated (ROI), hydroxyl radical 
(OH•) and superoxide (O₂-•) and reactive nitrogen intermediates (RNI), nitric 
oxide (NO•) and peroxynitrite (ONOO-)(Hussain et al, 2003). Primarily thought to 
be anti-microbial, these molecules are formed due to the activities of host 
enzymes such as NADPH oxidase, myeloperoxidase and nitric oxide that are 
regulated by inflammatory signaling pathways. Importantly, ROI and RNI lead to 
oxidative damage and nitration of DNA bases that increases the risk of DNA 
mutations(Hussain et al, 2003) . Cells have intrinsic mechanisms by which they 
avoid unregulated proliferation or the accumulation of DNA mutations. These 
mechanisms include but do not limit to tumor suppressor pathways that mediate 
cell cycle arrest, DNA repair, apoptosis and senescence. In the condition of DNA 
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damage or oncogenic activation, cells either repair their DNA and prevent 
mutations or initiated cells will undergo cell death(Rakoff-Nahoum, 2006). In the 
scenario of massive cell death as seen in infection or non-infectious tissue injury, 
lost cells gets repopulated by the expansion of other cells, often undifferentiated 
precursor cells such as tissue stem cells(Rakoff-Nahoum, 2006). There are two 
pre-requisites for this: Some cells amongst the dying population must survive the 
injury, and then these cells must expand to maintain cell numbers for a proper 
functioning tissue(Rakoff-Nahoum, 2006). Many inflammatory pathways play an 
important role to mediate these two prerequisites of tissue repair(Chen et al, 
2003; Wang et al, 2005). In a addition to its physiologic role in mediating tissue 
repair or as a strategy in host defense to infection, the inflammatory response 
may play an important role in providing survival and proliferative signals to 
initiated cells, thereby leading to tumor promotion(Rakoff-Nahoum, 2006). 
Direct evidence for a link between tumorigenesis and either host defense or 
tissue repair has been reported in numerous studies. (Rakoff-Nahoum, 2006). 
The Wnt/β-catenin pathway plays a vital role in both the maintenance of the 
steady-state proliferative compartment and tumorigenesis of tissues(Beachy et 
al, 2004). Molecules like COX-1 and -2, which are involved in the synthesis of 
prostaglandins that mediate the tissue repair process in the alimentary tract 
(Brown et al, 2007; Houchen et al, 2000; Morteau et al, 2000) play pivotal roles in 
tumor development at these sites(Chulada et al, 2000; Oshima et al, 1996). 
Moreover, key supportive evidence to support the role of these processes has 
come from studies showing that dedicated tissue injury and wound supports cell 
survival, tumor growth and neoplastic progression(Rakoff-Nahoum, 2006). 
Injection of Rous sarcoma virus (RSV) into chickens leads to the tumor growth at 
the site of injection, moreover sarcomas may form at other sites of the chicken if 
that site is wounded(Dolberg et al, 1985). The development of these wound-
related tumors can be attenuated by glucocorticoids and may be mediated by the 
actions of transforming growth factor-β (TGF-β) and fibroblast growth factors 
(FGFs) (Martins-Green et al, 1994; Sieweke et al, 1989; Sieweke et al, 1990). 
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Tumor growth is enhanced in wounded limbs by the experimental induction of 
paracrine factors such as TGF-β and bFGF in wound fluid, in a B16 melanoma 
adoptive transfer study(Hofer et al, 1998). 
Studies investigating the role of NF-κB (transcription factor central to the 
induction of inflammation) in tumorigenesis has provided some more detailed 
focus on the role of inflammation in tumor promotion. Greten et al. used a model 
of azoxymethane (AOM) induced colitis associated cancer (CAC),  which 
develops multiple rounds of inflammation and leukocyte tissue infiltration caused 
by colonic epithelial cell toxin, dextran sulfate sodium (DSS) 
administration(Greten et al, 2004). This mouse model system makes it very clear 
that chronic inflammation augments tumorigenesis, as when one dose of AOM is 
given without DSS cycling, no tumors arise in the mice(Rakoff-Nahoum, 2006). It 
was observed that inactivation of the classical NF-κB pathway in colonic 
epithelial cells by conditional deletion of the IκB kinase β (IKKβ) protein resulted 
in a substantial decrease in the frequency of visible tumors, indicating the one of 
the mechanisms of tumorigenesis(Greten et al, 2004). Importantly, NF-κ 
signaling in epithelial cells was necessary for the inhibition of apoptosis in short 
time after administration of one round of AOM and DSS, perhaps by the induction 
of anti-apoptotic factors like Bcl-XL(Rakoff-Nahoum, 2006). Thus after intestinal 
epithelial injury (DSS) and the addition of a mutagen (AOM), NF-κB provides a 
survival signal to the initiated cells. Importantly, IKKd of AOM and DSS, perhaps 
by the induction of anti-apoptoepithelial cell survival as a protection against both 
infectious and non-infectious injuries (Chae et al, 2006; Chen et al, 2003; Egan et 
al, 2004) and host defense pathways in the intestinal epithelium(Elewaut et al, 
1999). In another study, a similar role for NF-κB in survival of initiated cells was 
reported in Mdr2-deficient mice a chronic inflammation model of spontaneous 
hepatocellular carcinoma,(Pikarsky et al, 2004). In this model, NF-κB activation 
was restricted by selectively expressing super-repressor of degradation of IκB in 
hepatic epithelial cells. Increase in the number of apoptotic hepatocytes was 
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found that is correlated with a decreased frequency of tumors compared to Mdr2-
/- mice with degradable IκB (Pikarsky et al, 2004). 
Tumor promotion depends upon not only the survival of initiated cells, but also 
their exponential expansion. Various inflammatory mediators such as eicanosids, 
cytokines and chemokines are capable of stimulating the proliferation of both 
untransformed and tumor cells(Balkwill & Mantovani, 2001). Mice that lack in 
TNF have fewer skin tumors upon administration of the phorbol ester TPA and 
the mutagen DMBA(Moore et al, 1999). NF-κB activation in myeloid cells has 
been reported to play a critical role in the production of TNF as a inflammatory 
mediator of tumor growth in both the AOM/DSS model of CAC(Greten et al, 
2004) and mutagen-induced hepatocellular carcinoma upon administration of 
diethylnitroseamine (DEN)(Maeda et al, 2005). In both of these models, myeloid 
cells that were defective in activating NF-κB signaling via the classical pathway, 
there was impaired production of TNF and other inflammatory mediators, 
proliferation of dysplastic epithelium, and a reduction in both the frequency and 
size of tumors compared to the WT mice(Maeda et al, 2005).  
1.4 Mast cells in cancer 
1.4.1 Mast cell subsets and tissue distribution 
Mast cells (MC) are tissue-resident sentinel cells. MC progenitors (MCP) have 
been suggested to branch off very early from hematopoietic stem cells (Chen et 
al, 2005a) or alternatively to differentiate late in the myeloid lineage from the 
granulocyte monocyte progenitor and have a common precursor with 
basophils(Arinobu et al, 2009). At least two distinct subpopulations of rodent MC 
have been identified based on morphologic characteristics, tissue localization, 
and protease content(Befus et al, 1982; Enerback, 1966; Enerback et al, 1986; 
Metcalfe et al, 1997). Mucosal MC can be distinguished from connective tissue 
MC by expression of chymase instead of tryptase and for lower expression of 
heparin in the secretory granules. Human MC are also divided into two types 
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depending on the expression of tryptase, chymase, and other proteases in their 
granules(Irani et al, 1986). MC that contains only tryptase are referred to at MCT 
and typically colocalizes with T cells in the respiratory and intestinal mucosa. MC 
that contain tryptase, chymase, and other proteases, such as carboxypeptidase 
A and cathepsin G, are referred to as MCTC and are found in connective tissues, 
including skin, submucosa of the gastrointestinal tract, breast parenchyma, 
myocardium, lymph nodes, conjunctiva, and synovium. In mice, mature MC are 
rarely present outside the connective tissues. In the intestine, isolated MC are 
detected in the mid-crypt region along with epithelial stem cells. Affinity of mature 
MC to stem cells is also highlighted by their localization in the vicinity of hair 
follicle stem cells and their involvement in regulating the transformation from 
resting (telogen) follicle to active hair growth (anagen)(Arck et al, 2001). Other 
than these exceptions, MC normally migrate and reside in tissue as 
progenitors(Hallgren & Gurish, 2007). Both the intestine mucosa and hair follicles 
are rich sources of MCP(Gounaris et al, 2007; Kumamoto et al, 2003). 
Committed but undifferentiated MCP reside within the lymph hematopoietic 
system comprising the bone marrow, spleen, peripheral blood, mesenteric lymph 
node, and gut mucosa. These progenitors differentiate into chymase-expressing 
mature MC upon challenge(Chen et al, 2005a; Kasugai et al, 1995; Rodewald et 
al, 1996). Primary MC expanded ex vivo have characteristics of both connective 
and mucosal MC irrespective of the tissue source. Extensive work has 
demonstrated plasticity of MC subsets in tissues(Gurish et al, 1995), showing 
that subtype classifications are not rigid and may be shifting within the tumor 
microenvironment. For example, MC that mediate immunosuppression in mice in 
tolerant allografts have been suggested to be distinct from other MC(Lu et al, 
2006). Different subsets of MC infiltrate tumors at different stages of tumor 
progression. In benign adenomatous polyps of polyposis mouse strictly 
intraepithelial chymase-expressing MC are found(Gounaris et al, 2007), while 
MC infiltrating invasive carcinomas in mice are predominantly found in the 
invasive borders of tumors, as well as in tumor stroma, the muscularis mucosa 
and submucosa, and typically express tryptase(Maltby et al, 2009).  
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1.4.3 Mast cell arsenal of effector molecules 
MC produce three categories of effector molecules. One category includes those 
effector molecules, which are stored in granules such as serotonin, histamine, 
heparin, tryptase, and chymase(Khazaie et al, 2011). Another includes those that 
are synthesized de novo upon cell stimulation such as lipid mediators (PAF), 
prostaglandins (PDG2), and leukotrienes (LTB4, LTD4). Lastly, a large variety of 
cytokines that are Th1-associated (IFN-γ, IL-2, IL-3, GM-CSF, and TNF-α), Th2-
associated (IL-4, IL-5, IL-6, IL-10, IL-13, IL-33, and GM-CSF), or TH17-biased 
(TGF-β, IL-6, IL-1β, and TNF-α), chemokines and angiogenic factors including 
vascular endothelial growth factor(Boesiger et al, 1998) and tryptase(Blair et al, 
1997) as well as proteases including tryptases, chymases, cathepsins, and 
carboxypeptidase(Khazaie et al, 2011). Release of mediators by MC occurs 
either within minutes of activation (immediate acute) or over hours (delayed) 
depending on whether these are pre-made and stored in granules for immediate 
release or require de novo synthesis. IL-1β, IL6, and TNF-α released by MC are 
proinflammatory cytokines that can generate TH17 cells, inactivate Treg, or 
otherwise render them pro-inflammatory. MC are a source of preformed TNF-
α(Gordon & Galli, 1990), which also works as an autocrine MC stimulatory factor, 
and its elimination negatively impacts MC density in the gut(Gounaris et al, 2007). 
MC release TNF-α after incubation with bacteria, providing a potent chemotactic 
factor for neutrophils(Echtenacher et al, 1996; Malaviya et al, 1996; Mannel et al, 
1996). The MC-deficient W-sh mice have chronic intestinal inflammation while 
TNF-α-deficient mice have increased mortality in the “cecal ligation and puncture” 
model compared with wild-type mice(Maurer et al, 1998). Other MC-derived 
products that contribute to the influx of neutrophils and control microbes, include 
leukotriene B4 (LTB4), human tryptase βI, macrophage inflammatory protein 
(MIP)-1α (CCL3), MIP-1β, MIP-2, monocyte chemoattractant protein-1, RANTES 
(CCL5), and IL- 8 (CXCL8)(Feger et al, 2002). MC can produce large quantities 
of IL-1β(Bochner et al, 1990) that may be processed by MC chymase or 
potentially by caspase-1 in an Nlrp3 inflammasome-dependent manner(Nigrovic 
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et al, 2010). It is also known that MC can induce production of IL-1β by 
macrophages, at least in the pathogenesis of rheumatoid arthritis(Nigrovic et al, 
2010). IL-1β has a key role in chronic inflammatory reactions that help tumors 
flourish(Cook et al, 2010; Mantovani et al, 2008). IL-1β is also an important 
angiogenesis mediator regulating the synthesis of angiogenesis factors. A 
previous study has shown that human MC produce angiogenesis factor IL-8, 
when stimulated with IL-1β(Kim et al, 2010). It is tempting to speculate a 
connection between NLRP3 inflammasome activation in MC and cancer since 
NLPR3 and IL-1β are associated with environmental silica and asbestos 
carcinogenesis(Dostert et al, 2008). Of the long list of cytokines that can be 
released by MC, IL-10, and TGF-β deserve particular attention due to their role 
as immune-suppressive mediators that also generate induced Treg (iTreg). 
(Depinay et al, 2006). Secretion of IL-10 by MC has been implicated in down-
regulation of antigen-specific immune responses by mosquito bites(Depinay et al, 
2006). However, MC also respond to IL-10 differentially depending on the cellular 
source and level of activity. IL-10 can inhibit MC degranulation by suppressing 
MC IgE receptor expression and signaling (Kennedy Norton et al, 2008)while 
blocking antibodies to IL-10 can hinder antigen-induced recruitment of MCP to 
the lungs of C57BL/6 mice(Jones et al, 2010). In the mouse, at least five different 
chymases (mMCP-1, mMCP-2, MMCP-3, MMCP-4, and MMCP-5) and three 
different granule-associated tryptases (mMCP-6, mMCP-7, mMMP-
11/transmembrane tryptase) have been described(Huang et al, 1998). C57BL/6 
mice are defective in mMCP7 leaving them with mMCP6 as the major 
tryptase(Ghildyal et al, 1994). Expression of proteases in mouse MC is strictly 
related to the type of MC. Thus, mucosal MC express mMCP-1 and mMCP-2, 
whereas connective tissues MC express mMCP-3, mMCP-4 mMCP- 5, mMCP-6, 
mMCP-7, and carboxypeptidase(Miller & Pemberton, 2002; Stevens et al, 1994). 
MC have significant cyclooxygenase and lipoxygenase activity and generate 
inflammatory lipid metabolites of arachidonic acid(Khazaie et al, 2011). In mice, 
the major cyclooxygenase products of MC are prostanglandin-D2 (PGD2) and 
prostaglandin E2, and the major lipooxygenase products are LTC4, LTD4, and 
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LTE3 (Galli et al, 2005)LTB4 a MC product of 5-lypoxygenase is a 
chemoattractant for MC progenitors (Weller et al, 2005) and was recently shown 
to be a potent polyposis promoting factor in mice(Cheon et al, 2011). Human MC 
also produce LTB4, although in much smaller quantities than PGD2 or LCT4. MC 
are a source of platelet activating factor, and platelets are known to augment the 
growth and dissemination of primary tumors by promoting angiogenesis, immune 
evasion, and tumor extravasation(Jain et al, 2010). Release of certain mediators 
by MC requires degranulation (Khazaie et al, 2011. Degranulation is responsible 
for release of proteases as well as powerful anticoagulants such as heparin, 
chymase, and tryptase(Khazaie et al, 2011. Mechanisms of MC degranulation 
are best described in the context of the development of immediate 
hypersensitivity(Khazaie et al, 2011. The cross-linking of FcεRI, the high affinity 
IgE receptor, by allergen- or tumor-specific immunoglobulin IgE on MC is the 
primary trigger for the rapid release of their granules by exocytosis(Blank & 
Rivera, 2004). PI3K plays a key role in MC biology including degranulation 
(Figure 2) (Kim et al, 2008b).  
 
Figure 2. Downstream targets of phosphoinositide-3-kinase (PI3K) in 
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activated mast cells [Modified and adapted from (Kim et al, 2008b)] 
MC treated with LY294002 (PI3K inhibitor) or inhibition of PI3K by over-
expression of the dominant negative inhibitor Δp85 leads to a significant decline 
in MC degranulation via antigen-induced Ca2+ signals(Ching et al, 2001). MC 
may also be activated by “alternative,” IgE -independent pathways, such as 
aggregation of low-affinity FcγRIII IgG receptors by IgG/antigen complexes, c-Kit, 
and pattern recognition Toll-like receptor mechanisms, activation of the 
complement receptors (C3aR, C5aR, CR2, CR4) by exposure to chemokines, 
anaphylatoxins C3a and C5a, fragments of fibrinogen, and fibronectin (Johnson 
et al, 1975; Marshall, 2004; Prodeus et al, 1997; Wojtecka-Lukasik & Maslinski, 
1992). A recent study suggests that the release of microparticles from activated T 
cells induces MC degranulation and release of cytokines via the MAPK pathway 
independent of IgE(Shefler et al, 2010). These alternative pathways are thought 
to work through vesicle-mediated degranulation which involves small aliquots of 
granule-associated material that detach from the granule membrane for selective 
paracrine or endocrine transport to the cell exterior(Crivellato et al, 2010; Dvorak, 
2005). This degranulation pattern has frequently been observed in MC infiltrating 
areas of chronic inflammation or tumors (Dvorak & Kissell, 1991; Dvorak et al, 
1991). The alternative mechanism appears to be responsible for MC release of 
tumor-promoting cytokines and lipid mediators, particularly in early stages of 
cancer initiation such as in benign adenomatous polyps where degranulation of 
MC is not a major event(Gounaris et al, 2007).  
1.4.4 Human studies show correlation between mast cells and cancer 
progression 
A number of studies have documented correlations between the presence of MC 
and tumor development(Coussens et al, 1999; Imada et al, 2000; Ribatti et al, 
2000; Ribatti et al, 2003; Takanami et al, 2000; Terada & Matsunaga, 2000; 
Toth-Jakatics et al, 2000). MC infiltration in tumor is an independent prognostic 
factor and predictor of poor outcome in prostate cancer(Nonomura et al, 2007) 
27	   	  
and has been heralded as a novel prognostic marker(Johansson et al, 2010). 
Expression of c-Kit has been shown to predict recurrent disease and is 
suggested to be a marker of fibro-epithelial phyllodes tumors of the breast(Tan et 
al, 2005), but a recent report attributes this expression to the presence of 
infiltrating MC(Djordjevic & Hanna, 2008). High MC score is associated with 
unfavorable prognosis in patients with follicular lymphoma treated with immune-
chemotherapy(Taskinen et al, 2008). Increased MC counts, tumor size, and 
lympho-vascular invasion are associated with an adverse prognosis in Merkel 
cell carcinomas(Beer et al, 2008). MC infiltration in Hodgkin lymphoma also 
demonstrated a poor prognosis associated with infiltration of CD30L-expressing 
MC(Molin et al, 2002). Intriguingly, this effect appears to occur independent of 
MC-mediated effects on angiogenesis(Glimelius et al, 2005), potentially via direct 
interaction between MC and Hodgkin and Reed–Sternberg cells expressing 
CD30. MC are etiologically associated with the formation of neurofibromas in 
human neurofibromatosis1 patients(Yang et al, 2006). Tumor promotion by MC is 
attributed to the release of mediators of angiogenesis and recruitment of 
macrophages, neutrophils, and eosinophils (Figure 3) (Maltby et al, 2009).  
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Figure 3. Schematic representation of mast cell functions at different 
stages in colonic polyp/tumor progression and formation [Modified and 
adapted from (Maltby et al, 2009)]. 
High MC density together with angiogenesis was predictive of poor clinical 
outcome in colorectal cancer(Acikalin et al, 2005; Gulubova & Vlaykova, 2009; 
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Yodavudh et al, 2008a), lung cancer(Imada et al, 2000), and pancreatic 
cancer(Strouch et al, 2010). Positive correlation between MC and microvessel 
densities was observed in colorectal cancer (Acikalin et al, 2005; Gulubova & 
Vlaykova, 2009; Yodavudh et al, 2008a)and lung cancer(Carlini et al, 2010; 
Ibaraki et al, 2005), supporting the involvement of MC in the tumor angiogenic 
process. MC tryptase can be detected in the peripheral blood of pancreatic 
cancer patients, presumably reflecting the abundance of tumor-infiltrating 
MC(Strouch et al, 2010). In hepatocellular carcinoma, higher peritumoral MC 
density was associated with worse clinical outcomes and shorter recurrence free 
survival, while higher density of MC was related to increased probability of early 
recurrence. Interestingly, peritumoral Treg were positively correlated with MC 
density and reversely related to clinical outcomes(Ju et al, 2009a; Ju et al, 
2009b). 
1.5 PI3K pathway in cancer 
PI3Ks are the lipid kinases that phosphorylate the 3′-hydroxy group of PtdIns 
(phosphatidylinositol) and phosphoinositides (phosphorylated derivatives of 
PtdIns)(Vanhaesebroeck et al, 2010). The mammalian PI3Ks include eight 
enzymes that possess diverse roles in both vesicle trafficking and signal 
transduction. These enzymes are categorized into the categories known as class 
I, class II and class III, on the basis of their substrate preference and structure. 
However, only the class I PI3Ks have the ability to use PtdIns(4,5)P2 as a 
substrate to generate the important second messenger PtdIns(3,4,5)P3(So & 
Fruman, 2012). Certain proteins that contain a PH (pleckstrin homology) domain 
can specifically bind Ptdins(3,4,5)P3 and be recruited to membranes where PI3K 
is active(Lemmon, 2008). Thus class I PI3K acts as a signaling hub at the 
plasma membrane to change the lipid composition in a way that links 
transmembrane receptors to the organization of multiprotein complexes, also 
known as signalosomes(Fruman et al, 2000). The composition of these 
signalosomes and the specific PH domain-containing PI3K effector proteins that 
are recruited to these assemblies varies according to the receptor that is 
engaged in this event(So & Fruman, 2012). In most cells, the serine/threonine 
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kinase Akt [also known as PKB (protein kinase B)] is the key PI3K effector 
molecule and Akt phosphorylation is used as a common readout of PI3K 
activation(Fayard et al, 2010). There are two amino acid residues in Akt that are 
phosphorylated in a PI3K-dependent manner; Ser473 by TORC [TOR (target of 
rapamycin) complex with rictor (rapamycin-insensitive companion of mammalian 
TOR) and other proteins] 2 and Thr308 by PDK-1 (phosphoinositide-dependent 
kinase-1)(Fayard et al, 2010).  
The phosphatidylinositol-3_-kinase (PI3K) signaling cascade is involved in the 
regulation of various key cellular processes that are necessary for tumorigenesis 
including glucose metabolism, protein synthesis, cell survival, cell growth and 
proliferation, cell repair, cell migration, and angiogenesis (Katso et al, 2001). 
PI3K Signaling is regulated in several ways, hormones (estrogen, thyroid 
hormones), including growth factors (EGF, IGF1, FGF), vitamins, integrins, 
intracellular calcium, and the ras-dependent MAPK pathway(Saif & Chu, 2010). 
The PI3 kinase superfamily is composed of 12 members, and PI3K is made-up of 
two subunits: a 110-kDa catalytic subunit and an 85-kDaadaptor subunit. Upon 
cellular activation, the p85 subunit is recruited at the intracellular part of the 
growth factor receptor(Saif & Chu, 2010). Followed by dimerization with the p110 
subunit, which results in full enzymatic activity of PI3K and subsequent 
generation of PIP3, a lipid “second messenger” that possess the capacity of 
binding and activating proteins with PH domains, localizing them to the cell 
membrane(Saif & Chu, 2010). Phospholipid phosphatases, such as the 
phosphatase and tensin homologue PTEN and the inositol 5_phosphatase-2 
SHIP2PI3K inversely regulate PI3K the level of PIP3. The mechanism of this 
regulation of PI3K is via dephosphorylation of PIP3 into its inactive PIP2 
form(Katso et al, 2001). Moreover, signaling via the PI3K pathway is controlled 
by cross-talk with other extracellular signals and pathways, including hormones 
(estrogen, thyroid hormones), vitamins, integrins, intracellular calcium, and the 
ras-dependent MAPK pathway(Katso et al, 2001). 
The PI3K signaling pathway is constitutively activated in various malignancies 
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including CRC, prostate cancer, breast cancer, hematologic malignancies, 
glioblastoma multiforme, and lung cancer(Vivanco & Sawyers, 2002). This 
signaling pathway is activated by various mechanisms that include, activating 
mutations of PIK3CA, which is the gene encoding catalytic subunit of PI3K, gain-
of-function mutations of oncogenes encoding positive regulators of PI3K (HER2, 
EGFR, and RAS, c-Src), loss-of-function mutations affecting negative regulators 
of PI3K such as PTEN (ie, loss of PTEN expression/function), 
amplification/overexpression of receptor tyrosine kinases, and mutations of 
genes encoding downstream effectors of the PI3K signaling cascade (eg, PDK-1, 
Akt/PKB, RPS6KB1) (Saif & Chu, 2010). Akt plays a vital role in the gene 
transcription by NF-kB pathway, regulation of apoptosis and cell cycle 
progression by inhibitory phosphorylation of Cdk inhibitors such as 
p21WAF1/CIP1 and p27KIP1(Saif & Chu, 2010). It is known that cancer cells 
express high levels of activated Akt, and phosphorylation of Akt at S473 was 
significantly associated with poor prognosis in several types of 
cancers(Downward, 2004). Alterations in PI3K levels have been identified in 
CRC, gastric cancer, breast cancer, and ovarian cancer, while Akt amplification 
of Akt1, Akt2, and Akt3 have been found in breast, gastric, ovarian, pancreatic, 
and prostate cancers, respectively. There is increasing evidence suggesting that 
activation of various components of the PI3K/Akt pathway has prognostic 
importance in various malignancies(Saif & Chu, 2010). In addition, activation of 
PI3K has been identified as a potential mechanism by which cancer resist to 
chemotherapy, hormonal therapy, radiation therapy, and to various therapies 
targeting certain signaling pathways, such as trastuzumab and lapatinib(Saif & 
Chu, 2010). In all together, the frequent activation of the PI3K/Akt pathway in 
tumor cells and its potential role as a determinant of cellular drug resistance has 
made several individual components of this pathway attractive therapeutic 
targets for drug development(LoPiccolo et al, 2007). 
 
However tumor is a complex system that contains but is not restricted to tumor 
cells. In addition to tumor cells, inflammatory cells, blood vessels and connective 
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tissue form a supplementary network to form the tumor. Whenever PI3K is 
studied, it is studied in a complete tumor inclusive of this supplementary network, 
however less is known in context specifically with the PI3K activity in the 
inflammatory component of the tumor(LoPiccolo et al, 2007).  
 
1.6. PI3K in mast cells 
 
Receptor-mediated mast cell growth, differentiation, homing to their target 
tissues, activation and survival are all controlled, to varying degrees, by PI3K-
driven pathways, and PI3K deficient mice are devoid of mast cells (Cho et al, 
2008). Mast cells express the class 1A p85α, p85β and p50α regulatory subunit 
isoforms(Tkaczyk et al, 2003) and (Lu-Kuo et al, 2000) in addition to all three 
class 1A PI3K catalytic subunit isoforms, p110α, p110β, and p110δ and the class 
1B p110γ catalytic subunit (Ali et al, 2004; Okkenhaug et al, 2007). As Kit and 
the FcɛRI of MC initiate their signaling processes through the activation of 
tyrosine kinases, either intrinsically or by recruitment of cytosolic kinases(Gilfillan 
& Tkaczyk, 2006; Roskoski, 2005), they use class 1A PI3Ks to mediate 
subsequent downstream signaling events, whereas GPCRs, such as those for 
adenosine, prostaglandin (PG)E2, sphingosine 1 phosphate (S1P) and 
complement component C3a, mediate their responses via class 1B PI3K 
(Wymann et al, 2003) . The PI3K inhibitors, wortmannin and LY294002, have 
been reported in various studies to inhibit antigen-mediated degranulation and 
cytokine production in both rodent and human mast cells(Kim et al, 2008a; 
Okayama et al, 2003; Tkaczyk et al, 2003). Ironically, in some reports at least in 
human mast cells, these compounds fail to completely inhibit degranulation 
suggesting that although PI3K is essential for optimal degranulation of mast cells, 
PI3K-independent pathways might also regulate this response(Kim et al, 2008b). 
Studies using mouse bone marrow–derived mast cells (BMMCs) expressing a 
kinase-inactive mutant isoform of the p110δ catalytic subunit have demonstrated 
that p110δ is the major isoform responsible for antigen-mediated degranulation 
and cytokine production in mast cells(Ali et al, 2004; Ali et al, 2008). This 
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conclusion is further endorsed by the ability of the selective p110δ inhibitor, 
IC87114, to inhibit antigen-mediated mast cell activation and by its ability to 
inhibit the enhancement of antigen-mediated degranulation by stem cell factor 
(SCF)(Ali et al, 2004). By contrast, mast cells that are derived from the bone 
marrow of p85α and p85β knockout mice show normal antigen-mediated calcium 
flux and degranulation (Lu-Kuo et al, 2000; Tkaczyk et al, 2003), suggesting that 
the p110 catalytic subunit may use alternative regulatory subunits for its 
interaction with phosphorylated Gab2(Kim et al, 2008b). 
 
In addition to its role in mast cell mediator release, PI3K is also vital for mast cell 
chemotaxis, adhesion and homeostasis. This has been evidenced by the ability 
of wortmannin and LY294002 to effectively attenuate SCF-mediated cell 
migration, adhesion to fibronectin-coated plates, proliferation and survival in 
human and mouse mast cell cultures (Kim et al, 2008a). In addition, reduction in 
the levels of mast cells is observed in the peritoneal cavity, but not dorsal skin, of 
mice expressing a mutation in the PI3K binding site on Kit (Kissel et al, 2000). As 
with degranulation, mast cell adhesion, chemotaxis and homeostasis seem to be 
mediated by specific PI3K isoforms. In bone marrow derived murine mast cells 
(BMMCs) inactive for p110δ, there is a dramatic defect in SCF-mediated mast 
cell adhesion and chemotaxis compared with the responses observed in wild-
type mast cells (Ali et al, 2004). In addition, the ability of SCF to promote mast 
cell growth is significantly reduced in cells that express defective p110δ(Tkaczyk 
et al, 2003). Moreover, these attenuated responses are similarly observed in 
wild-type mouse mast cells incubated with the p110δ-selective PI3K inhibitor, 
IC87114, but not in cells incubated with the p110γ inhibitor, AS-252424(Ali et al, 
2004; Ali et al, 2008). In vivo, there is a loss of gastrointestinal and peritoneal 
mast cells in p85α-deficient mice (Fukao et al, 2002) and reduction in the number 
of mast cells in the dermis of ear, but not in the back skin, of p110δ inactive 
mutant mice compared with wild-type mice(Ali et al, 2004).  
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1.7. PI3K in myeloid derived inflammatory cell population 
 
In primary macrophages stimulated with the tyrosine kinase ligand colony-
stimulating factor 1 (CSF1), all class IA PI3K isoforms get involved in the 
regulation of Rac1, whereas p110δ selectively controls the activities of Akt, RhoA 
and PTEN, in addition to controlling proliferation and chemotaxis (Schmid et al, 
2011; Vanhaesebroeck et al, 2010). The prominent role of p110δ in these cells is 
indicative of being the main PI3K isoform that is recruited to the activated CSF1 
receptor (CSF1R) (Schmid et al, 2011; Vanhaesebroeck et al, 2010). In 
immortalized BAC1.2F5 macrophages, however, the CSF1R also engages 
p110α, which takes up a more prominent role in CSF1R signaling, in processes 
including Akt phosphorylation and regulation of DNA synthesis(Schmid et al, 
2011; Vanhaesebroeck et al, 2010). Cell migration, however, remains dependent 
mainly on p110δ. In other immortalized macrophage cell lines, such as IC-21 and 
J774.2, p110α is also found to be more prominently involved in CSF1-induced 
Akt phosphorylation, at the expense of p110δ(Schmid et al, 2011; 
Vanhaesebroeck et al, 2010). These data show that PI3K isoforms can be 
differentially monitored in distinct cellular contexts, with the dominant role of the 
p110δ isoform in Akt phosphorylation and proliferation being lost upon cell 
immortalization (Papakonstanti et al, 2008; Vanhaesebroeck et al, 2010). 
 
 In addition, a range of chemo- attractants activating G protein-coupled receptors 
(GPCRs), receptor tyrosine kinases (RTKs) and Toll-like/ IL-1 receptors 
(TLR/IL1Rs) initiate tumor inflammation by activating the PI3K in Gr1+CD11b+ 
myeloid cells (Schmid et al, 2011). Tumor derived chemoattractants stimulating 
myeloid cell RTKs, TLR/IL1Rs, and GPCRs activate a single PI3-kinase isoform, 
p110g, and a single integrin, a4b1, to promote myeloid cell recruitment to tumors 
and tumor progression(Schmid et al, 2011). Myeloid cell p110g is unexpectedly 
activated by RTKs and TLR/IL1Rs via Ras and p87, refuting current dogma that 
p110g is activated only by GPCRs. Moreover PI3Kg is a single convergent point 
controlling tumor inflammation and progression. Selective inhibitors of p110g 
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could thus serve as therapeutics to suppress tumor malignancy by blocking 
diverse pathway promoting tumor inflammation (Schmid et al, 2011).  
 
Animal modeling has shown that inhibition of PI3K is protective in experimental 
colitis (Brown et al, 2010; Gonzalez-Garcia et al, 2010; Lee et al, 2010; Strouch 
et al, 2010). Knowledge of the PI3K activity in pre-neoplastic tissue and tumor 
microenvironment is therefore important for understanding mechanisms of 
carcinogenesis and mode of action of PI3K targeting drugs that are currently 
being tested for clinical treatment of cancer (Chappell et al, 2011). 
1.8 Role of LY294002 as a PI3K inhibitor  
 
LY294002 is a chemical inhibitor of PI3K that has been used alone or in 
combination with chemotherapeutic agent to control tumor cell growth in vitro and 
in experimental animal models (Balkwill & Mantovani, 2001; Bernstein et al, 
2001; Ching et al, 2001; Erez & Coussens, 2011; Heinemann et al, 2000; Makitie 
et al, 2001; Meng et al, 2006; Ng et al, 2001; Philp et al, 2001; Vlahos et al, 
1994a; Workman, 2004). LY294002 competitively inhibits ATP binding to the 
catalytic subunit of PI 3-kinases and does not inhibit PI4-kinase, DAG-kinase, 
PKC, PKA, MAPK, S6 kinase, EGFR or c-src tyrosine kinases and rabbit kidney 
ATPase (Fruman et al, 1998; Fruman et al, 1999; Garlich et al, 2008; Rameh & 
Cantley, 1999; Scharenberg et al, 1998; Vlahos et al, 1995; Vlahos et al, 1994b). 
However, LY294002 is too insoluble for clinical investigation as a drug, although 
a prodrug derivative, SF1126 (Figure 4) has now entered human clinical trials as 
a pan-PI3K inhibitor, targeting cell growth, proliferation and angiogenesis(Garlich 
et al, 2008). 
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Figure 4. Chemical structure of (A) LY294002 and (B) pro-drug of 
LY294002 (SF1126), [Modified and adapted from (Garlich et al, 2008)] 
LY294002 can directly affect cancer cells proliferation, invasion and metastasis 
(Lewis & Pollard, 2006).  
1.9 Aims of the study 
 
The aim of this project was to test the role of PI3K/AKT in the inflammatory 
subsets and investigate whether their tumor promoting properties are dependent 
of PI3K/AKT.  
For these studies a chemical PI3K inhibitor LY294002 was used, an isoform of 
LY294002 called as SF1126 a pan-PI3K inhibitor is in human clinical trials. The 
potential efficacy of this approach was tested in ex vivo and in vivo experimental 
models of colon cancer. 
Specific aims were  
i) To investigate the pattern and status of PI3K/AKT activity and 
inflammatory cells (mainly mast cells and macrophages) in normal 
human colon, colitis without dysplasia, colitis induced dysplasia and 
ulcerative colitis induced invasive cancer.  
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ii) ii) To investigate the mechanistic role of PI3K/AKT in inflammatory 
cells in crosstalk with the tumor epithelium in context with the tumor 
promoting properties. 
iii)  iii) To investigate in vivo role of PI3K/AKT in inflammatory cells in 
context with tumor promotion and invasion in an experimental colitis 
associated cancer mouse model.  
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2.  
Materials 
and Methods   
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2	  Materials	  and	  Methods	  
2.1 Equipment and consumables 
Equipment and consumables Source 
Analytic balance scale Chemlab, USA 
Cell Culture Flasks BD Biosciences, USA 
Centrifuge (high speed) Lavei Centrifuge, USA 
Centrifuge/Falcon tubes (15 and 50 ml) BD Biosciences USA 
CO2 incubator  Thermoscientific, USA 
Coverslips  Tedpella, USA 
Cryostat (CM 3050)  Leica Microsystems, USA 
Cryotubes Thermoscientific, USA 
FACS Canto BD Biosciences, USA 
Fluorescence Microscope Zeiss, USA 
Gel documentation system Bio-Rad, USA 
Gloves  VWR, USA 
Hemacytometer glasses  Fisher Scientific, USA 
Ice machine Fisher Scientific, USA 
Laminar flow hood Microflow, Airclean, USA 
Light microscope  Leica, USA 
Magnetic stirring hot plate  Biomega, USA 
Microcentrifuge tubes (1,5 ml)  USAScientific, USA 
Microscope slides  Thermofisher, USA 
Microwave Scientificamerican, USA 
Neubauer hemacytometer  Sigma, USA 
Parafilm M  SPI, USA 
Paraffin embedding cassettes Leica microsystems, USA 
Pasteur pipettes Sigma-Aldrich, USA 
pH-meter LIS, USA 
Pipette tips (20 µL, 200 µL, 1000 µL) USA Scientific, USA 
Pipettes Gilson Middleton, USA 
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2.2 Media, supplements and reagents for cell culture 
Media, supplements and reagents 
for cell culture 
Source 
BSA (Bovine Serum Albumin) Sigma, USA 
DMSO (Dimethylsulfoxide, >99%) Sigma-Aldrich, USA 
DMEM (Dulbecco’s Modified Eagle 
Medium, high glucose 
Invitrogen, USA 
Dulbecco’s phosphate buffered saline  Invitrogen, USA 
FBS (Fetal Bovine Serum)  Sigma,USA 
HBSS, Hank’s buffered salt solution 
(10x) 
Sigma, USA 
HEPES  Cellgro, USA 
Gentamicin-Sulphate Cellgro, USA 
Glutamax Cellgro, USA 
McCoy’s 5A medium Sigma-Aldrich, USA 
Scintillation counter  LKB RackBeta, USA 
Shaker (Unimax)  Heidolph, USA 
Spectrophotometer Labomed, USA 
Stericup-Filter (0,22 µm) Millipore, USA 
Thermomixer  Eppendorf, USA 
Tissue-tek based molds Sakura, USA 
TissueGnostics highthroughput imaging 
system 
TissueGnostics, USA 
Vortexer Gennie-2 LabX, USA 
Waterbath ISOTEMP Fisher Scientific, USA 
Weighing paper  VWR, USA 
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MEM non-essential amino acids Cellgro, USA 
PBS (Phosphate buffered saline)  Gibco/Invitrogen, USA 
Penicillin-Streptomycin  Cellgro, USA 
RPMI1640 Medium  Cellgro, USA 
Sodium chloride Sigma-Aldrich, USA 
Sodium Pyruvate CellGro, USA 
Stempro Lifetechnologies, USA 
Trypanblue Cellgro, USA 
Trypsin-EDTA Cellgro, USA 
 
 
2.3 Cytokines 
Cytokines Source 
Human Stem cell factor (SCF) for cell 
culture 
Sigma-Aldrich, USA 
Murine IL-3 Cell Signaling, USA 
Murine SCF Millipore, USA 
 
 
2.4 Kits 
DAB Kit  DAKO, USA Naphthol	  AS-­‐D	  Chloroacetate	  (Specific	  Esterase)	  Kit	  	   Sigma-Aldrich, USA 
 
 
2.5 Invitro assay sytems 
Invitro assay sytems Source 
Chemo TX sytems Neuroprobe, USA 
LS column Miltenyi Biotech, USA 
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Matrigel based-Invasion assay plate 
(24 well/12 insert) 
BD Biocoat, USA 
 
2.6 Chemicals and Biochemical 
Chemicals and Biochemical Source 
Ammonium hydroxide Sigma-Aldrich, USA 
Antibody diluent Dako, USA 
Biotin-16-dUTP Roche Diagnostic, USA 
Boric acid Sigma-Aldrich, USA 
Bromodeoxyuridine (BRDU) Sigma-Aldrich, USA 
BSA (Bovine Serum Albumin) Sigma-Aldrich, USA 
Calcium Chloride (CaCl2)  
Carboxyfluorescein succinimidyl ester 
(CFSE) 
Sigma-Aldrich, USA 
Cobalt chloride, Hexahydrate Sigma-Aldrich, USA 
Collagenase type IV Worthington Biochemicals, USA 
Dabco Sigma-Aldrich, USA 
DNase Sigma-Aldrich, USA 
DAPI (4’,6-Diamidino-2-phenylindol 
Dihydrochlorid) 
Invitrogen, USA 
D-Glucose Sigma-Aldrich, USA 
Dinitrophenol-bovine serum albumin 
(DNP-BSA) 
Sigma-Aldrich, USA 
Dinitrophenol-human serum albumin 
(DNP-HSA) 
Sigma-Aldrich, USA 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich, USA 
Eosin Y Sigma-Aldrich, USA 
Ethanol 100% Fisherscientific, USA 
Ficoll-paque GE-Healthcare, USA 
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Glacial acetic acid Sigma-Aldrich, USA 
Glycerin Sigma-Aldrich, USA 
Glycerol Sigma-Aldrich, USA 
Glycine Sigma-Aldrich, USA 
Heparin  StemCell Technologies Inc Canada 
Hematoxylin solution, (Mayer’s) Sigma-Aldrich, USA 
Hematoxylin solution, (Harris’s II) Sigma-Aldrich, USA 
Hematoxylin solution, (Gill’s II) Sigma-Aldrich, USA 
Hyaluronidase Sigma-Aldrich, USA 
Hydrochloric acid  Sigma-Aldrich, USA 
Isopropanol Sigma-Aldrich, USA 
Lithium carbonate Sigma-Aldrich, USA 
LY294002 Sigma-Aldrich, USA 
Magnesium Chloride (MgCl2) Sigma-Aldrich, USA 
Mercaptoethanol Sigma-Aldrich, USA 
Methanol Sigma-Aldrich, USA 
NP-40 Sigma-Aldrich, USA 
O.C.T. embedding medium for cryo-
sections 
Tissue-Tek, USA 
Paraffin wax Sigma-Aldrich, USA 
Percoll Sigma-Aldrich, USA 
Phloxine B Sigma-Aldrich, USA 
Phosphotase inhibitor I and II cocktail  Sigma-Aldrich, USA 
Piroxicam Sigma-Aldrich, USA 
Polyvinyl alcohol Sigma-Aldrich, USA 
PNAG (mM 4-nitrophenyl N- acetyl-β-
D-glucosaminide) 
Sigma-Aldrich, USA 
Potassium Phosphate (K2HPO4) Sigma-Aldrich, USA 
Potassium Chloride (KCl) Sigma-Aldrich, USA 
Protease Inhibitor Sigma-Aldrich, USA 
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Sodium Bicarbonate (NaHCO3) Sigma-Aldrich, USA 
Sodium Carbonate (Na2CO3) Sigma-Aldrich, USA 
Sodium Cacodylate Sigma-Aldrich, USA 
Sodium Citrate, Trihydrate Sigma-Aldrich, USA 
Sodium Chloride (NaCl) Sigma-Aldrich, USA 
Sodium Dodecyl Sulphate Sigma-Aldrich, USA 
Sodium Phosphate (Na2HPO4) Sigma-Aldrich, USA 
Sodium Tetraborate Sigma-Aldrich, USA 
Target-retrieval solution Dako, USA 
Terminal Transferase (TdT)  Roche Diagnostic, USA 
Thymidine 3[H] Amersham Biotech, USA 
Toluidine Blue powder Sigma-Aldrich, USA 
Tris-HCl Sigma-Aldrich, USA 
Triton X-100 Sigma-Aldrich, USA 
Wash Buffer 10X Dako, USA 
Xylene FisherScientific, USA 
Xylene-based mounting meium-
Micromount 
Leica microsystems, USA 
 
 
2.7 Antibodies 
 
2.7.1 Antibodies for FACS 
 
Rat anti human -PE CD11b, BD Pharmingen, USA 
Iso-type control -rat IgG2b K, BD Pharmingen, USA 
 
2.7.2 Antibodies for immunoblottting 
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Rabbit anti- human pAKTT308, Cell Signaling, USA 
Rabbit anti- human pAKTS473, Cell Signaling, USA 
Rabbit anti- human total AKT, Cell Signaling, USA 
Rabbit anti- human beta actin, Cell Signaling, USA 
Goat Anti-rabbit HRP, Dako, USA 
 
2.7.3 Antibodies for cell isolation 
Biotinylated anti-human CD11b alpha M chain, BD Biosciences, USA 
Streptavidin magnetic beads, Miltenyi Biotech, USA  
 
2.7.4 Antibodies for immunohistochemistry/immunofluorescence 
 
Rabbit anti- mouse/human pAKTT308, Cell Signaling, USA 
Mouse anti-human Tryptase, Neomarker-Labvision, USA 
Mouse anti-human CD68, Santacruz Biotech, USA 
Mouse anti-human Mac1, Santacruz Biotech, USA 
Anti-BRDU, Abcam, USA 
Goat anti-rabbit Alexafluor 488 (H+L), Life technologies, Invitrogen, USA 
Goat anti-mouse Alexafluor 594 (H+L), Life technologies, Invitrogen, USA 
Goat-anti Rabbit HRP, Dako, USA 
Streptavidin-HRP, Dako, USA 
 
 
2.2 Recipes 
 
2.2.1.Harris’ Hematoxylin and Eosin (H&E)  
46	   	  
Acid Alcohol Solution (1%) 
• Hydrochloric acid, 1 ml 
• 70% ethanol, 50 ml 
• Mix well. 
Ammonia Water Solution (0.2%) 
• Ammonium hydroxide (concentrated), 2 ml 
• Distilled water , 1000 ml 
• Mix well. 
Lithium Carbonate Solution (Saturated): 
• Lithium carbonate 1.54 g 
• Distilled water 100 ml 
• Mix well. 
Eosin-Phloxine B Solution 
Prepare the stock solutions first, and then create the working solution as needed. 
Eosin Stock Solution 
• Eosin Y, 1 g 
• Distilled water, 100 ml 
• Mix to dissolve. 
Phloxine Stock Solution 
• Phloxine B, 1 g 
• Distilled water, 100 ml 
• Mix to dissolve. 
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Eosin-Phloxine B Working Solution 
• Eosin stock solution, 100 ml 
• Phloxine stock solution, 10 ml 
• Ethanol (95%), 780 ml 
• Glacial acetic acid, 4 ml 
• Mix well. 
Procedure: 
• Heat to dissolve. Add 50 ml of 10% alcoholic hematoxylin solution and 
heat to boil for 1 minute. 
• Remove from heat and slowly add 2.5 g of mercuric oxide (red). 
• Heat to the solution and until it becomes dark purple color. 
• Cool the solution in cold-water bath and add 20 ml of glacial acetic acid 
(concentrated). 
• Filter. 
 
2.2.2 TUNEL 
 
TdT Buffer Stock Solution (125mM Tris-HCl, 1M Sodium Cacodylate, 1.25mg/ml 
BSA, pH 6.6) 
• Tris-HCl (MW 157.6), 1.97 g  
• Sodium cacodylate, Trihydrate (MW 214.0), 21.4 g  
• BSA, 0.125 g  
• Distilled water, 100 ml  
Adjusted to pH to 6.6 and aliquot were stored at –20 ºC. 
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Cobalt Chloride Stock Solution (25mM Cobalt Chloride in Distilled Water) 
• Cobalt chloride, Hexahydrate (MW 237.9), 0.6 g  
• Distilled water, 100 ml  
• Mixed to dissolve.  
 
Aliquot were stored at –20 ºC.  
   
TdT Reaction Buffer (25mM Tris-HCl, 200 mM Sodium Cacodylate, 0.25 mg/ml 
BSA, 1mM Cobalt Chloride) 
• TdT Buffer Stock Solution, 40 ul  
• Cobalt Chloride Stock Solution, 8 ul  
• Distilled water, 160 ul  
Mixed well and stored at –20 ºC 
  
TdT Storage Buffer (60mM K-phosphate, pH 7.2, 150mM KCl, 1mM 2-
Mercaptoethanol, 0.5% Triton X-100, 50% glycerol) 
      To make the buffer:  
• K2HPO4 (MW174.18), 1.05 g 
• KCl (FW 74.55), 1.12 g  
• Distilled water, 50 ml 
      Stir to dissolve and adjust pH 7.2 using concentrated HCl. Add 50 ml of 
glycerin (100% glycerol), 0.5 ml of Triton X-100, and 8 ul of 2-Mercaptoethanol 
(99% Solution). Store at –20 ºC 
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Enzyme Reagent 
• Terminal Transferase (TdT) (Roche Diagnostic), 4 ul  
• TdT Storage Buffer, 100 ul  
      Mix well and store at –20 ºC  
   
Label Reagent:  
• Biotin-16-dUTP (Roche Diagnostic), 4 ul  
• TdT Reaction Buffer, 1 ml  
      Mix well and store at –20 ºC  
   
TdT Reaction Mixture: 
  
• Enzyme Reagent, 100 ul 
• Label Reagent, 900 ul  
       Mix just before use. The remaining 100 ul of Label Solution can be used for 
negative control.  
             
Stop Wash Buffer (300mM NaCl, 30mM Sodium Citrate) 
• NaCl (MW 58.44), 1.75 g  
• Sodium citrate, Trihydrate (MW294.11), 0.88 g  
• Distilled water, 100 ml  
Mix to dissolve and store at room temperature. 
 
2.2.3 Gelvatol  
Step I 
100 ml solution of: 0.14M NaCl 
0.01M KH2PO4/Na2HPO4, pH 7.2 
50	   	  
To the 100 ml solution, slowly 25 g polyvinyl alcohol** was added while stirring 
(total volume will be more than 100ml) 
Stirred over night 
Adjusted pH to 7.2 the next day.  
Step II 
50ml Glycerol was added to the solution above and stir over night (at least 16 
Hours) 
Suspension was spinned to remove undissolved particles 
Aliquots were made and stored airtight, at least 4 C or colder.  
Store opened vials at RT. 
Before use: Dabco (Sigma) 100mg/ml final concentration was added. Vortexed 
well, then spun down in microfuge for 10 min at full speed.  
 
2.2.4 RIPA Buffer 
• Tris-Cl [pH 7.5], 10mM 
• NaCl, 500mM 
• SDS, 0.1 % 
• NP-40, 1% 
• Sodium deoxycholate,, 1% 
• EDTA, 2mM 
• and protease, phosphatase I and II inhibitor cocktail, 1% 
 
 2.2.5 Tyrode buffer 
• HEPES, 10 mM 
• NaCl, 130 mM   
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• D-glucose, 6.2 mM 
• KCl, 3.0 mM 
• CaCl2, 1.4 mM   
• MgCl2, 1.0 mM   
• and BSA, 0.1% 
 
2.2.5 Borate buffer  
• Sodium tetraborate , 7.6 g 
• Boric acid, 5.0 g 
Dissolve in in 4 L of water and adjust the pH to 8.5, which required 
approximately 100 µl of 10.0 m NaOH/L buffer. 
 
2.2.6 Carbonate buffer, 0.1 M, pH 9.0 
• 1.06 g Na2CO3 
• 0.840 g NaHCO3 
• Bring to 100 ml with distilled H2O 
• Filter sterilize through 0.22-µm nylon filter 
 
2.2.7 MACS Buffer 
• PBS pH 7.2,  
• EDTA, 2 mM 
• BSA, 0.5 % 
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2.3 Methods 
2.3.1 Primary and established cell lines 
2.3.1.1	  LAD-­‐2	  
 
LAD-2 cells are mature human leukemic cell lines. LAD-2 cells were gift from 
Cleaveland Clinic, USA. LAD-2 cells were grown in stempro medium (Sigma 
Aldrich) with 100 ng/ml Stem Cell Factor (SCF) at 37oC and 5% CO2.  
2.3.1.2	  HT-­‐29	  	  
 
HT-29 is human colon adenocarcinoma cell line. Packaged HT-29 cells were 
obtained from American Type Culture Collection (Manassas, VA, USA). HT-29 
cells were cultures in McCoy’s 5A medium with 10% compliment-heat inactivated 
fetal bovine serum, 1% Penicillin-Streptomycin, 1% MEM non-essential amino 
acid, 1% sodium pyruvate and 1% Glutamax.  
2.3.1.3	  CT44	  
 
The tumor cell line CT44 was generated by transfecting CT26 cells (a cell line 
derived from a chemically induced murine colon carcinoma) with a fusion protein 
of influenza hemagglutinin and EGFP(Chen et al, 2005b) and was a gift from Dr. 
Weissleder Ralph. 
CT44 were cultured in DMEM (Life Techonolgies, USA) with 10% compliment-
heat inactivated fetal bovine serum, 1% Penicillin-Streptomycin, 1% MEM non-
essential amino acid, 1% sodium pyruvate and 1% Glutamax.  
2.3.1.4	  Isolation	  and	  culture	  of	  gut	  derived	  mouse	  mast	  cells	  (GMMCs)	  
 
Primary cell culture of GMMCs was obtained by isolating mast cell progenitors 
from IL-10-/- mice colons. Mice colons were chopped using surgical blades and 
subjected to collagenase digestion in RPMI at 37oC for 20 min. The supernatant 
was centrifuged at 1600 rpm for 10 min at 37oC, pellet was mixed in 40 % Percoll 
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(made from 4 parts of 100% Percoll and 6 parts of 1X Hank's balanced salt 
solution) and underlayed with 60% Percoll (made from 6 parts of 100% Percoll 
and 4 parts of 1X Hank's balanced salt solution) and centrifuged at 2600 rpm for 
30 min (brake-off) at 37oC. Interphase was collected and plated in 25-cm2 flasks 
with complete RPMI 1640 complete (RPMI with 10% compliment-heat inactivated 
fetal bovine serum, 1% Penicillin-Streptomycin, 1% MEM non-essential amino 
acid and 1% Glutamax and 1% HEPES), 20 ng/mL IL-3 and 10 ng/mL stem cell 
factor (SCF) for 3 weeks. Purity of MC was checked using flow cytometry (Figure 
5).  
 
 
 
Figure 5. Purity checks of GMMCs gated at cKit+ScaI+FcerI+ cells. 
Figure depicts representative picture for GMMCs purity check. 
2.3.1.5	  Isolation	  and	  culture	  of	  Tumor	  infiltrating	  Leukocytes	  (TILs)	  
To obtain tumor infiltrating leukocytes surgical colon cancer tissue samples from 
3 patients bearing UC associated colon cancer were washed with (DMEM with 
0.5% penicillin/streptomycin, 10 µg/mL gentamycin sulfate), minced with surgical 
blades, digested using (750 U/mL type IV collagenase, Worthington Bio- 
chemical; 500 U/mg hyaluronidase, Sigma; 0.1 µg/mL DNase, Sigma) and 
subjected to Percoll gradient centrifugation (40–80%) in 15 ml falcon tubes.  
Tubes were centrifuged at 2600 rpm for 30 min at 37oC brake-off. Interphase was 
collected washed 3X with complete RPMI and centrifuged at 1600 rpm for 10 min 
at 37oC, pellet was resuspended finally in complete RPMI and incubated at 37oC. 
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2.3.2 Culture of established cell lines 
Cells were cultured in an incubator at 37°C and 5% CO2. Media were 
supplemented, if not indicated differently, with 10% [v/v] FBS and 10% 
compliment-heat inactivated fetal bovine serum, 1% Penicillin-Streptomycin, 1% 
MEM non-essential amino acid and 1% Glutamax. Media were prewarmed at 
37°C prior to use. FBS was heat-inactivated for compliments for 30 min at 56°C. 
For quantification and determination of the number of viable cells, cell 
suspension was diluted in 1:1 ration in Trypan blue solution (0.125%). 
Cells were counted using Neubauer counting chamber and coverslip. 
2.3.2.1	  Passaging	  of	  adherent	  cell	  lines	  
 
Media from 70-90% confluent cell cultures were aspirated and cells were washed 
twice with 10 ml PBS. After aspirating PBS, 3 ml 1xTrypsin was added and cells 
were incubated at 37°C and 5% CO2 until they were completely detached. 
Trypsin was inactivated by addition of 10% FBS-supplemented culture medium. 
Cells were thoroughly resuspended followed by determination of cell 
concentration and split ratio. 
2.3.2.2	  Cryostorage	  of	  eukaryotic	  cell	  lines	  
 
Established cell lines were frozen at -80 °C short-term storage and at liquid 
nitrogen at 320 F for long-term storage. Cells were pelleted at 1600 rpm for 10 
min. Aliquots of 3x106-8x106 cells were resuspended in heat-inactivated FCS and 
10% (v/v) DMSO in a total volume of 1 ml in cryotubes. To allow a constant 
decrease in the temperature at a rate of 1 °C per minute, cryotubes were placed 
in a freezing container filled with isopropanol. Subsequently, cryotubes were 
immediately transferred to the -80 °C freezer for overnight and then liquid 
nitrogen for infinity. 
2.3.2.3	  Thawing	  of	  cells	  
 
In order to avoid the toxic side effects of DMSO in freezing medium, thawing of 
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cells was performed as fast as possible. Cryotubes were placed in the waterbath 
at 37°C until a small piece of ice was still visible in the cryotube. Prewarmed 
culture medium was added drop by drop in the cryotube and then sucked in the 
pipette and subsequently cell suspension was transferred to 15 ml falcon tube in 
total of 10 ml of volume. After centrifugation at 1600 rpm for 10 min, supernatant 
was removed and pellet was carefully washed two times in the culture medium 
and finally resuspended in fresh culture medium in a new culture flask. Media 
were changed 24 h later, in order to remove the remnants of toxic dimethyl 
sulphoxide (DMSO) and dead cells. Cells were passaged after 2-3 days 
depending on cell growth rate. 
2.3.2 Tissue and tumor specimens 
Paraffin embedded specimens of normal, non-inflamed colon from 8 patients who 
had surgery for non-malignant lesions like colonic AVM or diverticular disease 
were used as control [normal group]. Additionally, surgical specimens from 12 
UC patients with active colitis [colitis group], 7 UC patients with active colitis , 
dysplasia (dysplasia group) and 7 UC patients with colitis and  invasive colorectal 
cancer (cancer group) were obtained from Rush University Medical Center, 
Chicago. All procedures were approved by Rush University Medical Center 
Institutional Review Boards.  
2.3.3 Mice 
IL-10-/- mice and C57LB6 mice were obtained from Jackson laboratories. Mice 
were maintained under specific pathogen-free conditions at Northwestern 
University Animal Care Facility, and Animal Care Usage Committee of 
Northwestern University approved all experiments. IL-10-/- mice (6 weeks old) 
were transferred to conventional housing and allowed 1 week to acclimate. 
2.3.3.1	  Piroxicam	  and	  LY294002	  treatment	  
 
To synchronize colitis, 6-week-old IL-10-/- mice were fed pellet-chow containing 
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piroxicam (Sigma) for 2 weeks; for first week 65mg/250g piroxicam was fed 
followed by 85 mg/250g the next week (Harlan Teklad custom diet). LY294002 
(Sigma) were IP-injected at 50 mg/kg dissolved in 20% dimethyl sulfoxide 
(Sigma) every other day (Figure 6). Untreated mice received dimethyl sulfoxide.  
 
 
 
Figure 6. Timeline of colitis induction with piroxicam in IL-10_/_ mice 
and LY294002 treatment [Modified and adapted from (Lee et al, 2010)]. 
2.3.3.2	  Bromodeoxyuridine	  (BRDU)	  incorporation	  
 
Mice were injected intra-peritoneally with 1 mg of bromodeoxyuridine (BrdU; 
Sigma) 2 hours before death. 
2.3.3.3	  Fixing	  and	  embedding	  of	  mice	  colon	  
 Colons, were collected, cleaned for feces using PBS, fillet-laid opened and fixed 
in 10% formalin for 12 hours, followed by rolling and placing in embedding-
cassettes in 70% ethanol until paraffin embedding. Colons in embedding 
cassettes were dehydrated for paraffin embedding (water to paraffin) as per 
following steps:  
• Colons were passed through 70% ethanol, 2 changes, 1h each  
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• Followed by, 80% ethanol, 2 changes, 1h each  
• 95% ethanol, 2 changes, 1h each  
• 100% ethanol, 3 changes, 1h each  
• Xylene or substitute (i.e. Clear Rite 3), 3 changes, 1h each  
• Paraffin wax (56-58ºC), 2 changes, 1.5h each  
• and finally tissues  were embedded into paraffin blocks  
2.3.4 Chemical staining 
2.3.4.1	  Hematoxylin	  and	  Eosin	  staining	  (H&E	  staining)	  
4 µm thick paraffin sections were cut and placed on charged glass slides, 
subsequently air-dried, baked in hot-air oven at 50oC for 30 min and 
deparaffinized in two changes of xylene for 10 minutes each. Next, sections were 
re-hydrated in 2 changes of absolute alcohol for 5 minutes each followed by 95% 
alcohol for 2 minutes and 70% alcohol for 2 minutes. Sections were washed 
briefly in distilled water and stained in Harris hematoxylin solution for 8 minutes. 
Subsequently the sections were washed in running tap water for 5 minutes and 
placed in 1% acid alcohol for 30 seconds followed again by washing with tap 
water for 1 minute. Next, bluing was performed using 0.2% ammonia water or 
saturated lithium carbonate solution for 30 seconds to 1 minute. Sections were 
washed in running tap water for 5 minutes, rinsed in 95% alcohol for 10 dips and 
counterstain in eosin-phloxine solution for 30 seconds to 1 minute. Finally, 
sections were dehydrated through 95% alcohol with 2 changes of absolute 
alcohol for 5 minutes each, cleared in 2 changes of xylene for 5 minutes each 
and mounted with xylene based mounting medium. 
2.3.4.2	  Chloroacetate	  esterase	  staining	  	  
4 µm thick paraffin sections were cut and placed on charged glass slides, 
subsequently air-dried, baked in hot-air oven at 50oC for 30 min and 
deparaffinized in two changes of xylene for 10 minutes each. Next, sections were 
re-hydrated in 2 changes of absolute alcohol for 5 minutes each followed by 95% 
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alcohol for 2 minutes and 70% alcohol for 2 minutes. Sections were washed 
briefly in distilled water and sections were stained with Naphthol-AS-D 
chloroacetate for 20 min, washed in tap water for 5 min and counterstained with 
Hematoxylin Gills II for 30 seconds. Finally sections were washed in water and 
dehydrated through 95% alcohol with 2 changes of absolute alcohol for 5 
minutes each, cleared in 2 changes of xylene for 5 minutes each and mounted 
with xylene based mounting medium. 
2.3.4.3	  Toluidine	  Blue	  Staining	  
4 µm thick paraffin sections were cut and placed on charged glass slides, 
subsequently air-dried, baked in hot-air oven at 50oC for 30 min and 
deparaffinized in two changes of xylene for 10 minutes each. Next, sections were 
re-hydrated in 2 changes of absolute alcohol for 5 minutes each followed by 95% 
alcohol for 2 minutes and 70% alcohol for 2 minutes. Sections were washed 
briefly in distilled water and sections were stained with Toluidine Blue working 
solution for 20 minutes, washed in tap water for 5 min. Finally sections were 
washed in water and dehydrated through 95% alcohol with 2 changes of absolute 
alcohol for 5 minutes each, cleared in 2 changes of xylene for 5 minutes each 
and mounted with xylene based mounting medium. 
2.3.4.4	  BRDU	  staining	  
4µm thick paraffin sections were cut and placed on charged glass slides, 
subsequently air-dried, baked in hot-air oven at 50oC for 30 min and 
deparaffinized in two changes of xylene for 10 minutes each. Next, sections were 
re-hydrated in 2 changes of absolute alcohol for 5 minutes each followed by 95% 
alcohol for 2 minutes and 70% alcohol for 2 minutes. Sections were washed 
briefly in distilled water. Sections were washed in 0.1M Phosphate Buffered 
Saline (PBS) (pH 7.4) with 1% Triton X100 (3x for 5 minutes). Sections were 
incubated in HCl (1N) for 10 minutes on ice to break open the DNA structure of 
the labeled cells. This was followed by HCl (2N) for 10 minutes at room 
temperature before moving them to incubator for 20 minutes at 37°C. 
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Immediately after the acid washes, Borate buffer (0.1M) is added to buffer the 
cells for 12 minutes at room temperature. Samples were then washed in 0.1M 
PBS (pH 7.4) with 1% TritonX100 (3x 5 minutes) at room temperature. Next, 
sections were incubated in 0.1M PBS (pH 7.4) + 1% TritonX100 + Glycine (1M) + 
1% BSA (1hr) prior to incubating overnight at room temperature with anti-BrdU. 
Following the incubation overnight sections were washed in 0.1M PBS (pH 7.4) 
with 1% TritonX100 (3x 5min). Finally, sections were labeled with HRP labeled 
secondary antibodies, washed in PBS 2x for 5 minutes, counterstained with 
Hematoxylin Gill’s II for 30 seconds, washed in water, dehydrated in 95% and 
100% ethanol, cleared in xylene and mounted in xylene based mounting 
medium.   
2.3.4.5	  TUNEL	  staining	  
4 µm thick paraffin sections were cut and placed on charged glass slides, 
subsequently air-dried, baked in hot-air oven at 50oC for 30 min and 
deparaffinized in two changes of xylene for 10 minutes each. Next, sections were 
re-hydrated in 2 changes of absolute alcohol for 5 minutes each followed by 95% 
alcohol for 2 minutes and 70% alcohol for 2 minutes. Sections were washed 
briefly in distilled water. Sections were pretreated using proteinase K digestion 
method, followed by incubation of sections in 3% H2O2 in PBS for 10 minutes to 
block endogenous peroxidase activity, incubated in TdT Reaction Buffer for 10 
minutes, followed by TdT Reaction Mixture for 1-2 hours at 37-40 °C in 
humidified chamber. Reaction was stopped using stop wash buffer for 10 
minutes. Sections were incubated with Streptavidin-HRP in PBS for 20 minutes 
at room temperature, followed by DAB for 1-2 minutes, washed in running tap 
water for 5 minutes and counterstained with Gill's hematoxylin for 30 seconds. 
Sections were dehydrated through 95% ethanol for 5 minutes, 100% ethanol for 
2x for 3 minutes, cleared in xylene for 2x for 5 minutes and mounted with xylene 
based mounting medium. Sections were washed in intermittent steps with PBS-
Tween 20 for 3x for 2 minutes each. 
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2.3.5 Immunohistochemistry for pAKT or Tryptase staining 
4 µm thick paraffin sections were cut and placed on charged glass slides, 
subsequently air-dried, baked in hot-air oven at 50oC for 30 min and 
deparaffinized in two changes of xylene for 10 minutes each. Next, sections were 
re-hydrated in 2 changes of absolute alcohol for 5 minutes each followed by 95% 
alcohol for 2 minutes and 70% alcohol for 2 minutes. Sections were washed 
briefly in distilled water and antigen retrieval was performed at de-cloaking 
chamber at 120oC for 30 seconds and 90oC for 10 seconds using Dako target-
retrieval solution, peroxidase blocking was performed using Dako peroxidase 
block for 20 min and sections were additionally blocked using 1% bovine serum 
albumin (BSA).  Rabbit anti-mouse/human pAKT or Mouse anti-human Tryptase 
was applied for overnight at 1:50 dilution (in Dako antibody-diluent) at 4oC, next 
day washed with 2X with Dako wash buffer 5 minutes each and incubated with 
Dako anti-rabbit HRP or Dako anti-mouse HRP secondary antibodies for 1 hour 
at room temperature. Sections were washed 2X with Dako wash buffer 5 minutes 
each and DAB substrate was applied for 60 seconds and reaction was stopped in 
tap water for 5 minutes. Sections were finally counterstained using Gill’s II 
hematoxylin, washed in water, dehydrated through 95% ethanol for 5 minutes, 
100% ethanol for 2x for 3 minutes, cleared in xylene for 2x for 5 minutes and 
mounted with xylene based mounting medium. 
2.3.6 Double Immunofluorescence  
2.3.6.1	  Double	  Immunofluorescence	  staining	  for	  CD68	  and	  pAKT	  	  
4 µm thick paraffin sections were cut and placed on charged glass slides, 
subsequently air-dried, baked in hot-air oven at 50oC for 30 min and 
deparaffinized in two changes of xylene for 10 minutes each. Next, sections were 
re-hydrated in 2 changes of absolute alcohol for 5 minutes each followed by 95% 
alcohol for 2 minutes and 70% alcohol for 2 minutes. Sections were washed 
briefly in distilled water and antigen retrieval was performed at de-cloaking 
chamber at 120oC for 30 seconds and 90oC for 10 seconds using Dako target-
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retrieval solution, peroxidase blocking was performed using Dako peroxidase 
block for 20 min and sections were additionally blocked using 1% bovine serum 
albumin (BSA).  Rabbit anti- human pAKT and Mouse anti-human CD68 was 
applied for overnight at 1:50 dilution (in Dako antibody-diluent) at 4oC, next day 
washed with 2X with Dako wash buffer 5 minutes each and incubated at 1:150 
dilutions with anti-rabbit Alexafluor488 and anti-mouse Alexafluor594 secondary 
antibodies for 1 hour at room temperature in dark. Sections were washed 2X with 
Dako wash buffer 5 minutes each incubated with 4',6-diamidino-2-phenylindole 
(DAPI) for 15 minutes. Sections were finally washed in PBS 3x for 5 minute each 
and mounted with Gelvatol.  
2.3.6.2	  Double	  Immunofluorescence	  staining	  for	  Mac1	  and	  pAKT	  	  
5 µm thick frozen sections embedded in OCT were cut, placed on glass charged 
slides and incubated in PBS for 10 minutes or until sections are free from OCT at 
room temperature. Sections were fixed in ice-cold methanol at -20oC for 15 
minutes, washed 2x in PBS at room temperature and blocked with 1%BSA. ).  
Rabbit anti-human pAKT and Mouse anti-human Mac1 was applied for overnight 
at 1:50 dilution (in Dako antibody-diluent) at 4oC, next day washed with 2X with 
Dako wash buffer 5 minutes each and incubated at 1:150 dilutions with anti-
rabbit Alexafluor488 and anti-mouse Alexafluor594 secondary antibodies for 1 
hour at room temperature in dark. Sections were washed 2X with Dako wash 
buffer 5 minutes each incubated with 4',6-diamidino-2-phenylindole (DAPI) for 15 
minutes. Sections were finally washed in PBS 3x for 5 minute each and mounted 
with Gelvatol.  
2.3.7 TissueGnostics 
TissueGnostics Tissue/Cell High Throughput Imaging and Analysis System and 
semi-automated image acquisition microscope was used to acquire 200X 
magnification brightfield and fluorescence images throughout the section. Images 
were stitched in Adobe Photoshop Program and analyzed using ImageJ 
software. Total nuclei count was calculated using particle analysis software for 
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either hematoxylin or DAPI positive nuclei. 
2.3.8 Immunoblotting for MC and TILs 
LAD-2 MC or tumor infiltrating leukocytes (TILs) either treated with carrier DMSO 
or 10 µM LY294002 for 1 hour at 37oC were washed 3X in PBS for 5 minutes 
each and centrifuged at 1000 rpm for 10 minutes, pellet was used for 
immunobloting.  Whole-cell extracts were prepared in RIPA buffer. Proteins 
(30ug) were separated by SDS-PAGE, transferred following standard protocols. 
Immunoreactive proteins were detected with antibodies to phospho-AKT T308, 
phospho-AKT S473, total AKT (Cell Signaling) and beta-actin (Sigma) using the 
HRP-conjugated secondary antibodies and SuperSignal chemiluminescent 
reagent (Thermo Scientific). 
2.3.9 ß- hexososaminidase release (mast cell degranulation) assay 
For degranulation assays GMMCs were stimulated overnight using mouse anti-
DNP IgE 1ug/ml concentration and LAD-2 MC were stimulated overnight using 
human anti-DNP 1ug/ml concentration.  Next day cells were harvested, excess 
IgE was washed with Tyrode buffer and treated for 120 minutes either with 10 µM 
LY294002 or the carrier and subsequently challenged with DNP-BSA or DNP-
HSA from Sigma at 100ng/ml for 30 min. The supernatant was collected and 
stored at 4oC the pellet was lysed with 0.1% TritonX. The 20 µl of supernatant or 
pellet lysate were incubated with 1 mM 4-nitrophenyl N- acetyl-β-D-
glucosaminide (PNAG) for 60 minutes at 37oC and reaction was stopped with 
200 µl carbonate buffer (0.1 M, pH 10). ß-hexosaminidase release in the 
supernatant was measured at 405 absorbance and interpreted as the % of total 
cellular (lysate + supernatant) ß-hexosaminidase.  
2.3.10 Conditioned medium 
For the production of conditioned medium, 2x106/ml LAD-2 MC or GMMCs or 
1.5x106/750 µl TILs were treated with carrier DMSO or 10 µM LY294002 for 1 
63	   	  
hour washed 4x with serum-free medium and kept in fresh culture for 1 week 
(LAD-2 MC or GMMCs) and 72 hours (TILs) at 37oC and 5% CO2. The 
conditioned medium was removed, filtered using 0.22-µm filters, and used for 
medium transfer experiments.  
2.3.11 Macrophage Migration assay  
2.3.11.1	  Isolation	  of	  CD11b	  from	  blood	  of	  healthy	  donors	  	  
Peripheral blood from healthy donors was collected in heparinized vials. Blood 
was transferred in the 15 ml falcon tubes. Ficoll-Paque from GE Healthcare was 
underlayed and tubes were centrifuged at 1600 rpm for 20 minutes with break-off 
at 37oC. Interphase of mononuclear cells was collected, washed 2X in PBS with 
1% BSA. Mononuclear cells were incubated at 1:50 of anti-human biotinylated 
anti-CD11b, alpha M chain (BD Biosciences) on ice for 15 minutes. Cells were 
washed 3x in PBS with 1% BSA and centrifuged at 1600 rpm for 10 minutes. 
Pellet of mononuclear cells was brought up in streptavidin magnetic beads 
(Miltenyi Biotech) and incubated for 10 minutes in ice. Finally, cells were washed 
3x in PBS with 1% BSA and centrifuged at 1600 rpm for 10 minutes and finally 
resuspended in MACS buffer. LS column  (Miltenyi Biotic) was pre-wetted with 
MACS buffer 3x before passage of cells, cells in MACS buffer were passed 
through LS column, finally column was washed 3x with MACS buffer to remove 
any unbound cells from the column. Attached CD11b+ cells were collected in 
MACS buffer and checked for the purity using flow cytometry. 
2.3.11.2	  Migration	  assay	  
 
For migration assay, CD11b+ cells were resuspended in serum-free RPMI at 
106/ml concentration in 22.5 µl and seeded in triplicates on top well of 5 micron 
uncoated 96-well Chemo TX system  (Neuro Probe, Gaithersburg, MD).  The 
bottom well was loaded with 29 µl of Stempro medium with 100 ng/ml SCF, or 
LAD-2 mast cell conditioned medium without or with 10µm LY294002, or 
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conditioned medium obtained from LAD-2 mast cells that were pretreated with 10 
µM LY294002.  After 3 hours of incubation at 37oC, the migrated CD11b+ cells 
were counted with trypan blue on hemocytometer. Assays were performed in 
triplicates and repeated three times with different healthy donors. 
 
2.3.12 Colon cancer epithelial cell proliferation assay 
2.3.12.1	  Cell	  harvestaion	  
 
HT-29 cells or CT44 cells were allowed to grow to the confluency of 50-60% in 
75-cm2 cell culture flasks. Cells were washed 2x with 10 ml PBS pre-warmed at 
37oC in water bath, PBS was aspirated, 3 ml of 1x Trypsin was added cells to the 
cells and flask was incubated at 37oC until cells wells trypsinized and detached 
completely. 10 ml of complete McCoy’s 5A medium or complete DMEM was 
added to stop the action of trypsin on the respective cell lines and cell-number 
was counted using 10 µl of the cell suspension and 10 µl of the Trypan blue dye 
at (1:1 ratio) in the Neubauer’s Chamber. Cells were transferred to a 15 ml falcon 
tube and centrifuged for 1600 rpm for 10 minutes. Pellet was resuspended and 
washed 3x using 10 ml of McCoy’s 5A or complete DMEM and subsequent 
centrifugation at 1600 rpm for 10 minutes at 37oC.  
2.3.12.2	  Epithelial-­‐cell	  proliferation	  assay	  
 
Pellet obtained from cell harvestation was finally resuspended in the McCoy’s 5A 
or complete DMEM, such that final concentrations of cells were 1 x 104/ 100 µl.  
HT-29 cells were seeded in triplicates in 100 µl per well in a sterile 96 well flat-
bottom plate for 24 hours at 37oC and 5% CO2. For HT-29 proliferation assay 
studies, next day 100 µl of either fresh complete McCoy's 5A or Stempro with 
100 ng/ml SCF or LAD-2 mast cell conditioned medium or LAD-2 mast cell 
conditioned medium with 10 µM LY294002 or conditioned medium obtained after 
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10 µM LY294002 treatment of LAD-2 mast cells were added and incubated for 
24, 48 and 72 hours at 37oC and 5% CO2, separate 96 well plates were used for 
each time-point analysis. For CT44 epithelial proliferation assay, next day either 
100 µl of conditioned medium obtained from carrier DMSO or 10 µM LY294002 
treated GMMCs was added and incubated for 24, 48 and 72 hours at 37oC and 
5% CO2, separate 96 well plates were used for each time-point 
analysis.0.5mCurie of [3H] Thymidine was added to each well and incubated for 6 
hours after 24, 48 and 72 hours time points. HT-29 and CT44 cell proliferation 
was measured using a scintillation counter (LKB RackBeta; Wallac).  
2.3.13 Colon cancer epithelial cell invasion assay 
Cells were harvested as described in cell harvestation section of colon cancer 
epithelial cell proliferation assay.  
Matrigel-based invasion assay plates were kept at -20oC and were taken out only 
few hours before actual assay under sterile conditions in a Laminar-flow hood 
and were allowed to gain the room temperature. Inserts and invasion assay 
bottom chambers were added with 500 µl of pre-warmed, sterile serum-free 
respective medium  (McCoy’s 5A or DMEM) for 2 hours.  
2.3.13.1	  Invasion	  assay	  for	  the	  study	  of	  the	  role	  of	  PI3K/AKT	  in	  LAD-­‐2	  MC	  based	  colon	  
cancer	  epithelial	  invasion	  
 
Pellet for HT-29 cells obtained from cell harvestation was resuspended in serum-
free McCoy’s 5A medium such that the final concentrations of cells in the cell 
suspension was 6x104 cells/ml. Next, 500 µl of serum-free McCoy’s 5A was 
aspirated from the invasion assay bottom chambers and inserts. To the bottom 
chamber 750 µl of the Stempro medium with 100 ng/ml SCF, or LAD-2 mast cell 
conditioned medium without or with 10µm LY294002, or conditioned medium 
obtained from LAD-2 mast cells that were pretreated with 10 µM LY294002 were 
added. 3x104 colon cancer epithelial cells HT-29 were seeded in triplicates in 500 
µl per well of serum-free McCoy's 5A in the top wells (inserts) in the 24 well (12) 
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insert invasion assay plate. After 48 hours of incubation at 37oC and 5% CO2 the 
invasion assay was stopped. Medium from the inserts was aspirated and non-
invaded cells were removed; the inserts were passed through 2X methanol for 5 
minutes each for fixing the invaded cells in the membrane and subsequently 
staining with Toluidine blue working solution for 5 minutes. Invading cells were 
counted using a brightfield microscope. 
2.3.13.2	  Invasion	  assay	  for	  the	  study	  of	  the	  role	  of	  PI3K/AKT	  in	  TILs	  based	  colon	  cancer	  
epithelial	  invasion	  
 
Invasion assay for TILS was performed in two different experimental setus. In 
setup 1, after warming the invasion assay plate and pre-wetting for 2 hours with 
serum-free DMEM, 3 x 104 CFSE labeled HT-29 cells were seeded in triplicates 
in the top wells (inserts) of invasion assay plate and in the lower chamber 
conditioned medium from TILs was added. In experimental setup 2, CFSE 
labeled 3 x 104 HT-29 cells were seeded either alone, or in 1:1 ratio with TILs 
untreated or treated with 10 µM LY294002 in the top wells for co-culture, the 
bottom wells were filled with complete McCoy’s 5A.  After incubating the invasion 
assay plate for 48 hours at 37oC and 5% CO2, tumor invasion was manually 
recorded and quantified as described in 2.3.13.1. 
2.3.13.3	  Invasion	  assay	  for	  the	  study	  of	  the	  role	  of	  PI3K/AKT	  in	  GMMC	  based	  mouse	  
colon	  cancer	  epithelial	  invasion	  
 
3 x 104 CT44 cells were seeded in top wells in serum free DMEM in triplicates, in 
bottom wells conditioned medium obtained from LY294002 or carrier DMSO pre-
treated primary mouse mast cells (GMMCs) medium was added in the invasion 
assay chamber (BD biocoat). Remaining assay was performed as described in 
2.3.13.1. 
2.3.14 Statistical analysis 
All experiments were repeated 3 times and at least 10 mice were used in each 
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group. Comparison of groups was assessed using the Student t test. P values 
lower than 0.05 were considered statistically significant. 
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3. 
Results  
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3	  Results	  
 
Stromal interactions that sustain chronic inflammation and predispose to cancer 
are poorly understood. Experimental models of colitis implicate the PI3K pathway 
in activation of gut enterocytes and tissue remodeling. While mouse models are 
important for gaining mechanistic insights into diseases that affect us, validation 
of the findings in humans remains the only way to evaluate their clinical 
relevance. Here, in this study it is shown that in contrast to mouse models of 
colitis by far the greatest fraction of PI3K active cells are tissue infiltrating pro-
inflammatory cells. A potent inhibitor of PI3K that is currently in clinical use, in 
combination with ex vivo assays and animal modeling was used in this study to 
elucidate the contribution of PI3K activity towards recruitment of inflammatory 
cells and predisposition to cancer. These findings point to the stromal 
interactions as the prime site of action of PI3K inhibitors in prevention and 
therapy of inflammation induced colon cancer. 
3.1: Characterization and selection of the paraffin embedded colonic tissue 
specimens from patients	  
 
To understand the spatial distribution and kinetics of inflammation and PI3K 
activity in situ during progression from colitis to cancer, human surgical 
specimens were separated in four groups according to their histopathological and 
clinical findings namely 1) no colitis no dysplasia (designated “normal” in this 
study), 2) ulcerative colitis without dysplasia (colitis), 3) ulcerative colitis with 
dysplasia (dysplasia) and 4) ulcerative colitis with invasive colorectal cancer 
(cancer)(Figure 7A and Table 1-4) and the study was distributed in mucosal and 
submucosal findings (Figure 7B and 7C). For mucosal tissue data was analyzed 
from tissue above muscularis mucosa and extended to lumen, that included 
epithelium, lamina propria and mucularis mucosa. Tissue underneath muscularis 
mucosa was considered for the submucosal tissue analysis (Figure 7). 	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Figure 7. Categorization of patient tissue specimens using Haematoxylin 
and Eosin staining. (A) Tissuegnostic acquired stitched images of Normal, 
Colitis, Dysplasia and Invasive cancer. (B) H&E staining of mucosal 
tissue of Normal, Colitis (black arrow indicates ulcer), Dysplasia (black 
arrow indicates dysplastic crypts) and Invasive cancer. (C) H&E staining 
of submucosal tissue of Normal, Colitis, Dysplasia and Invasive cancer 
(black arrow indicates invaded crypts). Red arrows show mucosal and 
submucosal tissue. Red scale bar = 50 µm. 
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In total 8 normal, 11 UC without Dysplasia, 7 UC with Dysplasia and 8 UC with 
invasive Cancer patient specimen were used in this study.	  	   Sex	   Mean 
Age	   Race	   Disease Course (≥ 5 
years)	  
PanColitis 	   Active 
Colitis	  
Controls	   4/8	   49.8 
(34-73)	   4/8	   NA	   NA	   NA	  
UC without 
Dysplasia	   4/11	   39.2 (19-66)	   6/11	   7/11	   10/11	   8/11	  
UC with 
Dysplasia	   4/7	   53.4 (25-75)	   6/7	   3/7	   6/7	   6/7	  
UC with CRC	   6/7	   51.4 
(37-71)	   6/7	   5/7	   7/7	   4/7	  
 
Table.1 Patient Cohorts.   Sex is defined as ratio of male over total. Age is 
defined as age at time of biopsy with range.  Race is listed as Caucasian 
race versus other.  Disease course is defined as a diagnosed presence ≥ 5 
years.  “Active Colitis” is defined at time of biopsy as equal to or greater 
to mild colitis but does not include “quiescent” or inactive colitis. 
Controls defined as no dysplasia and no evidence of colitis.  NA=not 
applicable 
3.1.1 Ulcerative colitis patients without dysplasia used in the study  
In total 11 patient samples were used for immunohistochemical analysis in this 
study.	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Sex	   Race	   Age	   Disease Course 
(years)	   Disease Extent 	   Severity of Colitis	  
F	   AA	   40	   5	   Left	   S	  
F	   C	   58	   2	   Pan	   S	  
F	   AA	   33	   2	   Pan	   S	  
F	   C	   26	   3	   Pan	   M	  
F	   C	   21	   7	   Pan	   M	  
M	   C	   28	   >10	   Pan	   M	  
F	   AA	   66	   >10	   Pan	   Q	  
M	   C	   62	   >5	   Pan	   Q	  
M	   H	   44	   3	   Pan	   Q	  
F	   C	   19	   5	   Pan	   M	  
M	   H	   62	   5	   Pan	   S	  
 
Table 2. Ulcerative Colitis Patients Absent Colonic Dysplasia.  F=female, 
M=Male, C=Caucasian, AA=African American, H=Hispanic. Patients’ Age 
at time of biopsy is listed.  Colitis extent is defined as either “pan” colitis 
when extends proximally past the splenic flexure. Severity of colitis is 
defined as Q=quiescent, MI=mild, M=moderate, S=severe. 
3.1.2 Ulcerative Colitis patients with Dysplasia used in this study 
In total 7 patient samples were used for immunohistochemical analysis in this 
study.	  
73	   	  
Dysplasia	   Sex	   Race	   Age	   Disease Course 
(years)	   Disease Extent 	   Severity of Colitis	  
Low 	   M	   C	   74	   2	   Pan	   M	  
Low 	   F	   H	   54	   >20	   Pan	   M	  
High 	   F	   C	   75	   7	   Pan	   M	  
Low 	   M	   C	   46	   NA	   Pan	   MI	  
Low 	   F	   C	   25	   9	   Pan	   NA	  
Low 	   M	   C	   52	   3	   Left	   M	  
High	   M	   C	   48	   NA	   Pan	   M	  	  
Table 3. Ulcerative Colitis patients with Dysplasia.  Patients’ degree of 
dysplasia is defined as high or low grade dysplasia based on the 
maximum degree of dysplasia identified.  F=female, M=Male. 
C=Caucasian, H=Hispanic. Age at time of colectomy is listed.  Colitis 
extent is defined as either “pan” colitis when extends proximally past the 
splenic flexure. Severity of colitis is defined as Q=quiescent, MI=mild, 
M=moderate, S=severe. 	  
3.1.3 Ulcerative Colitis patients with invasive cancer used in this study 
In total 7 patient samples were used for immunohistochemical analysis in this 
study.	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Cancer	   Stage	   Tumor 
differentiation	   Sex	   Race	   Age	  
Length of 
Disease 
Course 
(years)	  
Disease 
Extent	   Severity of Colitis	  
Cancer 
1	   T2N0	   M	   M	   C	   71	   >10	   pan	   Q	  
Cancer 
2	   T3N0	   P	   F	   C	   45	   2	   pan	   M	  
Cancer 
3	   T2N0	   M	   M	   AA	   63	   1	   pan	   M	  
Cancer 
4	   T3N0	   M	   M	   C	   53	   >10	   pan	   Q	  
Cancer 
5	   T3N2	   W	   M	   C	   48	   >10	   pan	   M	  
Cancer 
6	   T3N1	   M	   M	   C	   43	   >10	   pan	   S	  
Cancer 
7	   T3N0	   P	   M	   C	   37	   >10	   pan	   MI	  
Table 4. Patients diagnosed with ulcerative colitis and associated 
colorectal cancers.  All cancers come from specimens with evidence of 
prior colitis in the location of the neoplasia at time of colectomy.  Tumor 
differentiation is defined as either W=well differentiated, M=moderately 
differentiated or p=poorly differentiated. Race defined as AA= African 
American, C=Caucasian. Age is defined as age at time of colectomy 
specimen. Disease extent= defined as pan=pancolitis extending 
proximally from the splenic flexure.  Severity of colitis is defined as 
Q=quiescent, Mi=mild, M=moderate, S=severe. 
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3.2 Immunohistological study of human patient tissue specimens 
3.2.1 Bone marrow derived pAKT positive cells progressively increase in 
colitis, dysplasia, and colon cancer 
Paraffin embedded tissue specimens from the patients (Table 1-4) were cut in 4 
µm thick sections and were stained using antibodies against pAKT. 
TissueGnostics high-throughput Imaging microscope was used to acquire 
pictures at 200X magnification of the entire tissue section. Images were stitched 
using Adobe Photoshop Program and mucosal and submucosal tissue-data 
analysis was performed using ImageJ software on 50 fields of vision. pAKT+ cells 
were detected by immunohistology in mucosa (Figure 8A) and sub-mucosa 
(Figure 8B).  
 
 
 
Figure 8. pAKT+ macrophages progressively infiltrate the colonic 
submucosa with progression to colitis and cancer. Representative 
immunohistochemical staining depicting pAKT+ (brown) cells in healthy 
and diseased human colonic (A) mucosa and (B) submucosa. Red scale 
bar = 50 µm. 
76	   	  
 
 
The mean frequencies of epithelial pAKT+ cells in mucosa did not show 
significant differences when comparing normal (0.59 ± 0.23) to colitis (0.74 ± 
0.13) to dysplasia (0.69 ± 0.13) and to invasive cancer (1.10 ± 0.17)(Figure 9A). 
The frequency of stromal pAKT+ cells infiltrating the mucosa in all cases 
outnumbered pAKT+ epithelial cells (compare Figure 9A and 9B). Significant 
increases in pAKT+ cells were detected in the stroma of the mucosa when 
progressed from “normal” (2.33 ± 0.65) to colitis tissue (6.83 ± 1.12, *P<0.05), 
but thereafter plateaued (Figure 9B) with no significant differences from colitis to 
dysplasia (5.81 ± 1.27) to invasive cancer (8.27 ± 1.48). By contrast the 
frequency of pAKT+ cells were steadily and significantly increased in the 
submucosa with each transition from “normal” (2.33 ± 0.65), to colitis (6.56 ± 
0.80, *P<0.05), to dysplasia (16.19 ± 4.70, *P<0.05) and finally to cancer (37.87 
± 7.39, *P<0.05), with cancer having the highest density of pAKT+ cells (Figure 
9C). 	  	  
	  
 
Figure 9. Quantification of pAKT+ cells in colonic mucosa and 
submucosa with progression to colitis and cancer. Bar graphs shows 
quantification of % mean ± standard error of positively stained cells of 
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pAKT per total nuclei in (A) mucosal crypt-epithelium (B) mucosal stroma 
and (C) submucosa of normal and diseased human colonic tissue. * P < 
0.05 represents the result of Student t test. 
 
3.2.2 Mast cell frequencies increase with progression to colitis and then 
cancer 
MCs are sentinel cells that are activated early in the process of intestinal 
carcinogenesis, and contribute to cancer initiation (Khazaie et al, 2011). In 
mouse models of cancer, MCs orchestrate further inflammatory reactions by 
mobilizing tumor associate macrophages (TAMs) (Cheon et al, 2011; Gounaris et 
al, 2007; Gounaris et al, 2008) It is known for long that MC recruit TAMs in 
human pancreatic cancer (Brown et al, 2010). To relate tissue MC densities to 
mobilization of TAMs in colitis progression to cancer paraffin embedded tissues 
were stained for MC-tryptase (Figure 10A and 10B). Images from 50 fields of 
vision were recorded for quantification by Tissuegnostics high-throughput 
imaging microscope for each mucosa and submucosa.  MCs were detected in 
mucosa (Figure 10A) and sub-mucosa (Figure 10B), of samples with colitis, 
dysplasia, and cancer.  
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Figure 10 Tryptase+ mast cell densities progressively increase in the 
colonic submucosa with progression to colitis and cancer. Representative 
immunohistochemical staining depicting tryptase (brown) positive mast 
cells in healthy and diseased human colonic (A) mucosa and (B) 
submucosa Red scale bar = 50 µm 
 
Relative densities and sub-tissue distributions of MC mirrored that of pAKT+ cells. 
Thus, MC frequencies in mucosa increased significantly from normal colon (4.75 
± 0.56) to colitis (14.17 ± 1.82, *P<0.05), but did not increase further as the 
disease progressed from colitis to invasive cancer (colitis: 14.17 ± 1.82; 
dysplasia: 15.54 ± 3.07; invasive cancer: 19.44 ± 3.74) (Figure 11A). In contrast, 
mean MC frequencies in sub-mucosa increased steadily as the disease 
progressed from normal (6.34 ± 0.99) to colitis (12.35 ± 1.86, *P<0.05), to 
dysplasia (33.54 ± 8.55, *P<0.05) and to invasive cancer (59.99 ± 7.09, *P<0.05) 
(Figure 11B). 	  	  
	  
 
Figure 11. Quantification of tryptase positive cells in colonic mucosa and 
submucosa with progression to colitis and cancer. Bar graphs show 
quantification of % mean ± standard error of positively stained cells of 
human mast cell tryptase per total nuclei in (A) mucosa and (B) 
79	   	  
submucosa of normal and diseased human colonic tissue. * P < 0.05 
represents the result of Student t test. 
3.2.3 Tumor Associated Macrophages frequencies increase with 
progression to colitis and then cancer 
MC are known to mobilize TAMs, and both critically contribute to tumor growth 
and invasion (Erreni et al, 2011; Khazaie et al, 2011; Maltby et al, 2009).To 
identify TAMs in tissue samples histologic sections were stained with antibodies 
to pan-macrophage antigen CD11b (Mac1) (Arnaout, 1990) and 
CD68(Heinemann et al, 2000; Strobl et al, 1995). Based on mouse modeling it 
has been suggested that chemo- attractants, growth factors, and pathogen 
associated molecular patterns initiate tumor inflammation by activating PI3-
kinase in CD11b+ myeloid cells (Schmid et al, 2011). To test this notion, double 
immunofluorescence staining for pAKT and macrophage markers was performed 
(Figure 12). The data was acquired and analyzed as described above for pAKT 
and Tryptase. There was abundant co-localization of pAKT with CD68 (Figure 
12A and 12B).  
 
 
 
Figure 12. CD68+ pAKT+ macrophages progressively infiltrate the colonic 
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submucosa with progression to colitis and cancer. Representative 
double-immunofluorescence staining depicting CD68 (Red), pAKT+ 
(Green), DAPI (blue) and CD68+ pAKT+ (Yellow) cells in healthy and 
diseased human colonic (A) mucosa and (B) submucosa. Red scale bar = 
50 µm. 
 
Densities of pAKT+ CD68+ TAMs were found in identical pattern with the 
densities of pAKT+ cells (Figure 13) in the mucosa when disease progressed 
from normal (2.33 ± 0.56) to colitis (4.77 ± 0.96), dysplasia (5.81 ± 1.27) and 
cancer (6.27 ± 1.14) (Figure 13A). Interestingly, the densities of pAKT+ CD68+ 
TAMs increased steadily from normal tissue (1.56 ± 0.44) to colitis (4.83 ± 0.67), 
dysplasia (12.58 ± 3.83) and cancer (34.54 ± 4.56) in the submucosa (Figure 
13B), showing the same pattern as pAKT+ cells. However, the recruitment of 
TAMs progressively in the disease was not restricted to pAKT+ CD68+ TAMs, but 
total CD68+ cell densities (inclusive of all pAKT±) also increased progressively in 
the submucosa from normal (2.13 ± 0.45), colitis (6.18 ± 0.84), dysplasia (18.81 ± 
4.23) to cancer (38.62 ± 4.51) (data not shown). In addition, the data was 
validated using total Mac1+ and Mac1+ pAKT+ cell densities in the disease 
progression, where similar pattern of recruitment to the total CD68+ and 
CD68+pAKT+ cell frequencies was observed (data not shown). 	  
	  
Figure 13. Quantification of CD68+ pAKT+ macrophages in colonic 
mucosa and submucosa with progression to colitis and cancer. Bar 
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graphs show quantification of % mean ± standard error of positively 
stained cells of human CD68+ pAKT+ macrophages per total nuclei in (A) 
mucosa and (B) submucosa of normal and diseased human colonic 
tissue. * P < 0.05 represents the result of Student t test. 
3.3 Role of PI3K/AKT in mast cells and macrophage migration  
3.3.1 LAD-2 mast cells posses phospho-AKT T308, phospho-AKT S473 
PI3K Is extremely necessary for mast cell biology, survival and function (Kim et 
al, 2008b). To ensure presence of PI3K/AKT and inhibition of PI3K activity by 
LY294002, first MC extracts were prepared for analysis of phospho-proteins. 
Proteins separated by gel electrophoresis and transferred to membrane were 
reacted with antibodies to phospho-AKT T308, phospho-AKT S473, total AKT 
(Cell Signaling) and beta-actin (Sigma). This analysis showed that pre-incubation 
of LAD-2 MC for 1 hour with 10 mM of LY294002 hindered T308-phosphorylation 
of AKT by 1.74 ± 0.15 fold and S473 by 4.01 ± 0.38 fold. (Figure 14A and 14B).  
 
	  
Figure 14. LY294002 attenuates pAKT levels in LAD-2 mast cells. A) 
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Immunoblot of total and phosphorylated AKT (Threonie/T308) and 
(Serine/S473) in LAD-2 mast cells untreated and treated with 10 µM 
LY294002 or T308, S473, AKT and beta actin. Bar graphs indicate 
quantitation of (B) the ratio of LAD-2 MC band intensity with LAD-2 MC 
treated with 10µM LY294002. * P < 0.05 represents the result of Student 
t test. 
3.3.2 MC regulate macrophage migration via PI3K signaling 
MC orchestrate secondary inflammatory reactions by recruiting other bone 
marrow derived cells (Khazaie et al, 2011; Maltby et al, 2009), including TAMs 
that critically contribute to CRC progression (Erreni et al, 2011). The hypothesis 
was to test if PI3K activity in MC is needed for their chemotactic potential. To test 
this hypothesis, LAD-2 human mast cell line was used. LAD-2 MC were pre-
incubated in the presence or absence of LY294002, washed three times and 
added back into culture to collect conditioned medium. The chemotactic activity 
of conditioned media was then tested by measuring migration of CD11b+ 
macrophages freshly prepared from human peripheral blood mononuclear cells 
(PBMC) through Chemo TX system.	  
To assay migration of macrophages the Chemo TX 5-µm pore size migration 
assay system was used. CD11b+ macrophages were isolated from the freshly 
drawn blood from healthy donors using anti-human CD11b-biotinylated antibody 
(BD Pharmingen) and columns (Miltenyi Biotech). Isolated CD11b+ cells were 
loaded in the top chamber and the conditioned mediums from LAD-2 mast cells 
were loaded in the bottom chamber. There was a significant migration of the 
CD11b+ macrophages to the bottom chamber as compared to similar setups 
where regular non-conditioned medium was used for comparison (*P<0.05) 
(Figure 15A, 15B and 15F).  Pre-treatment of LAD-2 MC with 10 mM LY294002 
abrogated the bioactivity of the conditioned medium in this assay and thus 
CD11b+ macrophage migration (*P<0.05, Figure 15C, 15D and 15F). Cd11b+ 
cells used in this study were at least 99% pure (Figure 15E).	  
83	   	  
 
Figure 15. LY294002 treatment attenuates mast cells associated 
macrophage migration. Representative images show the migration of 
CD11b macrophages in response to (A) Stempro + SCF (control/ LAD-2 
base growth medium), (B) CM (LAD-2 conditioned medium), (C) CM + 10 
µM LY294002 (CM with 10 µM LY294002) and (D) 10 µM LY pretreated 
CM (CM obtained after treatment of LAD-2 cells with 10 µM LY294002). 
(E) Purity of CD11b+ cells obtained after using either biotinylated Rat 
ant-human CD11b or biotinylated Rat IgG2bK (F) Quantification 
expressed in mean ± standard error of CD11b migration in response to 
conditions mentioned in (A-D) . Black arrows indicate migrated CD11b+ 
cells. Black scale bar = 20 µm. * P < 0.05 represents the result of Student 
t test. 
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3.4 PI3K activity in MC is indispensable for MC biological functions and MC 
dependent-tumor promoting properties 
3.4.1 PI3K/AKT is essential for the MC degranulation 
PI3K activity is essential for differentiation of MC, as well as their long-term 
survival and function (Kim et al, 2008b). Mature MCs produce various biologically 
active mediators, which are released either by secretion or by degranulation. In 
particular it has been reported that in mouse models of cancer, inhibiting MC 
degranulation abrogates tumor-promoting properties of MC (Soucek et al, 2007). 
Hence, next important investigation was to test the impact of different 
concentrations (5 and 10 µM) of LY294002 on MC degranulation, for this purpose 
human LAD-2 MC were used. Treatment of LAD-2 MC with LY294002 inhibited 
degranulation, the ß-hexososaminidase release (%) in carrier-treated/control 
(72.38 ± 5.78) was reduced after 5 µM LY294002 (47.76 ± 6.43, *P<0.05) and 10 
µM LY294002 treatment (39.82± 4.39, *P<0.05) (Figure 16).  
	  
Figure 16. LY294002 treatment attenuates LAD-2 human mast cell 
degranulation. Figure depicts % ß-hexosaminidase release from LAD-2 
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mast cells before and after treatment of 5 or 10 µM LY294002. * P < 0.05 
represents the result of Student t test. 
3.4.2 PI3K/AKT is essential for the MC dependent tumor proliferation and 
tumor invasion 
MC produce array of cytokines, chemokines and various growth factors, that 
plays an important role in the survival of tumor epithelium and cancer 
progression(Maltby et al, 2009). Hence next question was to study whether the 
soluble factors produced by MC enhance the proliferation and invasion of 
epithelial cancer cells, and whether it is governed by PI3K/AKT in mast cells 
(Brown et al, 2010). Also, the role of PI3K/AKT in MC in context with the 
proliferative response of HT-29 colon cancer cells was studied using human 
LAD-2 MC (Kirshenbaum et al, 2003). 	  
3.4.2.1	  PI3K/AKT	  is	  essential	  for	  the	  MC	  dependent	  ex	  vivo	  HT-­‐29	  cell	  proliferation	  
 
LAD-2 cell conditioned medium enhanced the rate of proliferation of HT-29 cells 
progressively at 24 (Figure 17A), 48 (Figure 17B) and 72 hours (Figure 17C) 
(*P<0.05). Next investigation was to test the effect of inhibition of PI3K by treating 
LAD-2 cells with 10 µM LY294002 and preparing conditioned medium from 
washed cells. Pre-incubation with LY294002 significantly reduced the ability of 
the LAD2 conditioned medium to stimulate proliferation of HT-29 cells, measured 
at three separate time-points (*P<0.05, Figure 17). Furthermore, direct effect of 
LY294002 treatment on the proliferative responses of HT-29 cells was studied. 
LY294002 was found to have direct inhibitory effects on the tumor cells. 
However, even in the presence of this inhibitor LAD2 conditioned medium elicited 
a significant proliferative response in the tumor cells (Figure 17). These 
observations suggest that PI3K activity in MC contributes to tumor proliferation 
and its inhibition by LY294002 is a critical event in suppression of tumor growth. 
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Figure 17. LY294002 treatment attenuates mast cells associated HT-29 
tumor proliferation. Figure depicts quantitation expressed as mean ± 
standard error HT-29 proliferation (A) post 24 hrs, (B) post 48 hrs and 
(C) post 72 hrs in response to the treatment of McCoy’s 5A (negative 
control), Stempro + SCF (internal control for LAD-2 CM), CM (LAD-2 CM), 
CM+ 10 µM LY294002 (CM with 10 µM LY294002) and 10 µM LY 
pretreated CM (CM obtained after treatment of LAD-2 cells with 10 µM 
LY294002). * P < 0.05 represents the result of Student t test. 
3.4.2.2	  PI3K/AKT	  is	  essential	  for	  the	  MC	  dependent	  ex	  vivo	  HT-­‐29	  tumor	  invasion	  
 
After establishing the role of PI3K/AKT in MC dependent HT-29 proliferation, next 
goal was to investigate whether PI3K activity and phosphorylation of AKT in MC 
contribute to tumor invasion. To test this hypothesis, in vitro invasion assays 
were performed with the HT-29 colon cancer cells in the presence or absence of 
LAD-2 conditioned medium. Since, LY294002 treated LAD2-CM attenuates HT-
29 proliferation by 40% at 48 hours, the HT-29 invaded cell count was 
normalized (reduced the cell number by 40% in Control/Stempto+SCF and LAD-
2CM groups for analysis and graphical representation). There was a significant 
increase in mean HT-29 cell invasion/well in Matrigel in response to LAD-2 MC 
conditioned medium (64.80 ± 6.92, *P<0.05) in comparison with the control 
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(11.40 ± 1.03 *P<0.05)  (Figure 18A and 18B). Invasion was attenuated when 
the conditioned medium was obtained from LAD-2 MC that had been previously 
treated with 10 µM LY294002 as described above (17.67 ± 1.45, *P<0.05, Figure 
17A and 17B). As with the proliferation response, LY294002 had direct inhibitory 
effect on the tumor cells. However, even in the presence of this inhibitor LAD2 
conditioned medium elicited a significant invasion response in the tumor cells 
(38.67 ± 4.91, *P<0.05, Figure 18A and 18B). These observations strongly 
suggest that MC promote tumor invasion and that this property of MC is PI3K 
dependent. Thus, release of tumor promoting agents by MC and potential 
contribution of MC to tumor growth and invasion were blocked by LY294002. 	  
 
Figure 18. LY294002 treatment attenuates mast cells associated HT-29 
tumor invasion. (A) Representative images of HT-29 invasion study in 
response to Stempro + SCF (internal control for LAD-2 CM), LAD-2 CM, 
CM + 10 µM LY294002 (LAD-2 CM with 10 µM LY294002) and 10 µM LY 
pretreated CM (CM obtained after treatment of LAD-2 cells with 10 µM 
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LY294002). Invaded cells can be seen as blue cells. (B) Quantification of 
mean ± standard error invaded HT-29 cells per well or chamber in 
response to conditions mentioned in (A). * P < 0.05 represents the result 
of Student t test. 
3.4.2.3	  PI3K/AKT	  in	  TILs	  promote	  ex	  vivo	  HT-­‐29	  tumor	  invasion	  
 
Next goal was to study the role of PI3K/AKT in tumor infiltrating leukocytes (TILs) 
that forms the tumor-stroma and investigate the link with tumor invasion. For this 
study, TILs were isolated from the freshly obtained ulcerative colitis associated 
cancer samples. TILs were checked for phosphorylation at Threonine 308 
residue (pAKT-T308) and Serine 473 residue of AKT (pAKT-S473), 10µM 
LY294002 treatment significantly attenuated pAKT-T308 1.62 ± 0.05 fold and 
pAKT-S473 3.53 ± 0.17 fold in comparison with the carrier treated pAKT-T308 
and pAKT-S473 (*P<0.05, Figure 19A and 19B).  
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Figure 19. LY294002 attenuates pAKT levels in TILs. A) Immunoblot of 
total and phosphorylated AKT (Threonine/T308) and (Serine/S473) in 
TILs untreated and treated with 10 µM LY294002. Bar graphs indicate 
quantitation of (B) the ratio of TILs band intensity with TILs treated with 
10 µM LY294002 for T308, S473, AKT and beta actin. * P < 0.05 
represents the result of Student t test. 
Next, tumor-infiltrating leukocytes (TILs) isolated from CRC tumors were 
measured for the ability to promote tumor cell invasion. By pretreating the TILs 
with LY294002 the dependence of the tumor invasion promoting activity on PI3K 
was tested. To address this question, TILs were isolated from fresh surgical 
specimens derived from tumors of colitis associated colon cancer patients. Two 
different setups were used. In the first setup tumor cells were added in top 
chamber and conditioned medium from the TILs (carrier or 10 µM LY294002 
pretreated) in the bottom chamber, and in the second setup the TILs were co-
cultured with the tumor cells. After normalization of HT-29 cell counts in 
Stempro+SCF, TILs CM and HT-29+TILs study groups, mean invasion of HT-29 
cells into matrigel was significantly enhanced by the TILs in both experimental 
setups (76.80 ± 5.67 for setup-1 and 133.80 ± 7.99 for setup-2, *P<0.05). 
Pretreatment of the TILs with 10 µM LY294002 significantly inhibited tumor 
invasion relative to treatment with CM from carrier-treated TILs or co-culture with 
carrier-treated TILs respectively (26.67 ± 6.93 for setup-1 and 57.00 ± 4.72 for 
setup-2, *P<0.05, Figure 20A, 20B and 20C). These results are compatible with 
those obtained with MC conditional medium and demonstrate that the PI3K 
inhibitor LY294002 inhibits production of mediators of tumor invasion by TILs, 
that include TAMs and MCs.  
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Figure 20. LY294002 treatment attenuates TILs associated HT-29 tumor 
invasion. (A) Representative images of CFSE labeled HT-29 invasion 
study in response to tumor infiltrating leukocytes (TILs) isolated from UC 
associated cancer patients. Red arrows show invaded HT-29. (B) 
Quantitation of mean ± standard error invaded HT-29 cells per well in 
the experimental setup-1 (HT-29 in top chamber and CM from TILs with 
or without 10 µM LY294002 pretreatment in bottom well) & (K) 
Quantitation of mean ± standard error invaded HT-29 cells per well in 
the experimental setup-2 (HT-29 in 1:1 coculture with TILs with or 
without 10µM LY294002 pretreatment in top chamber). Red scale bar = 
50 µm, * P < 0.05 represents the result of Student t test. 
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3.5 Pi3k/Akt inhibitor LY294002 attenuates mast cells, colitis, and cancer 
development in the IL-10-/- Piroxicam mouse model 
 
To further validate in vitro observations and to see if they also have central roles 
in progression of inflammation to cancer in the in vivo system, cancer prone 
colitis mice were treated with LY294002. IL-10-/- mice when treated with 
Piroxicam develop colitis with ulcers, followed by invasive cancer by day 56 
(mean invasive lesions 2.30 ± 0.26, Figure 21A and 21B) (Lee et al, 2010). 
LY294002 treatment reduced the incidence of invasive cancer in this model 
(0.100 ± 0.10, *P<0.05, Figure 21A and 21B).  
 
Figure 21. LY294002 attenuates development of cancer in IL-10-/- mice 
treated with Piroxicam. (A) Histological evaluation of IL-10-/- and IL-10-/- 
mice treated with LY294002. H & E staining at 100X & 200X 
magnification of IL-10-/- mice 56 days post Piroxicam ± LY294002 
treatment; black arrow indicates invaded colonic crypts. (B) Graphical 
representation of the mean frequencies ± error of invasive lesions in IL-
10-/- (10-/- treated with Piroxicam) and IL-10-/- mice+ LY (10-/- treated 
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with Piroxicam and LY294002. Red scale bar = 50 µm, * P < 0.05 
represents the result of Student t test. 
Also, LY294002 treatment reduced the frequency of Bromodeoxyuridine (BrdU) 
positive cells (*P<0.05, Figure 22A and 22E), increased apoptosis as measured 
by TUNEL (*P<0.05, Figure 22C and 22F), and reduced the pAKT levels within 
the crypt-epithelium (*P<0.05, Figure 22B and 22G) and stroma (*P<0.05, 
Figure 22D and 22H).  	  
 
Figure 22. LY294002 attenuates epithelial proliferation, induces 
apoptosis and restricts pAkt levels in IL-10-/- mice treated with 
Piroxicam. Histological evaluation of (A) BrdU staining in colon of IL-10-/- 
or IL-10-/- mice treated with LY294002 (note brown staining) (B) TUNEL 
staining on colon of IL-10-/- or IL-10-/- treated with LY294002 (C) pAkt 
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staining in colonic mucosal epithelium of IL-10-/- or IL-10-/- mice treated 
with LY294002. (D) pAkt staining in colonic stroma of IL-10-/- or IL-10-/-  
mice treated with LY294002. Graphical representation of the mean 
frequencies ± error of (E) % BRDU+, (F) %TUNEL+, (G) %pAkt+ epithelial 
and (H) %pAkt+ stromal cells per total nuclei in the colon of untreated 
and LY294002 treated Il-10-/- mice. Black arrows indicate pAkt+ cells. 
Red scale bar = 50 µm, * P < 0.05 represents the result of Student t test. 
In earlier studies a causative role for focal mastocytosis and pre-neoplasia in the 
mouse intestine has been reported (Gounaris et al, 2007; Khazaie et al, 2011). 
Thus, next goal was to investigate the effect of pi3k/akt inhibition on the 
frequencies of mast cells in the cancer. Chloroacetate esterase (CAE) staining 
was used to study the in vivo impact of LY294002 on MCs infiltrating the gut 
tissue. CAE is a cytochemical staining that stains MCs and granulocytes 
(Lichtman & Segel, 2005). LY294002 treatment inhibited the mean frequencies of 
tissue infiltrating CAE+ cell (0.262 ± 0.06) in comparison with control untreated 
mice (0.98 ± 0.09, *P<0.05, Figure 23A and 23B). 
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Figure 23. LY294002 attenuates the frequency of CAE positive cells in IL-
10-/- mice in vivo. (A) Representative images of CAE staining at 100X & 
200X magnification respectively of IL-10-/- mice 56 days post Piroxicam ± 
LY294002 treatment; black arrows indicate pink CAE positive cells. (B) 
Quantification of % mean ± standard error CAE+ cells per total nuclei in 
LY294002 untreated and treated IL-10-/- mice. Red scale bar in = 50 µm, 
* P < 0.05 represents the result of Student t test. 
Moreover, the effect LY294002 treatment on the in situ degranulating mast cells 
using Toluidine Blue staining was studied. Frequency of in situ degranulating MC 
(purple MCs), found predominantly in the sub-mucosa (site of invasion) was 
significantly attenuated (% mean 30.12 ± 2.98) in comparison with the non-
LY294002 treated mice  (85.02 ± 1.57, *P<0.05, Figure 24A and 24B).  	  
 
 
Figure 24. LY294002 attenuates in situ mast cell degranulation in IL-10-
/- mice (A) Representative images of toluidine blue staining at 100X & 
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1000X magnification respectively of IL-10-/- mice 56 days post Piroxicam 
± LY294002 treatment, black arrow indicates magnified, purple 
degranulating or blue non-degranulating mast cells. (B) Quantitation of 
% mean ± standard error in vivo mast cell degranulation per total mast 
cells in the colon of the LY294002 untreated or treated IL-10-/- mice (% 
in situ degranulation = total purple mast cells X 100 / total mast cells in 
LY294002 untreated or treated IL-10-/-). Red scale bar in = 50 µm, Black 
scale bar = 20 µm, * P < 0.05 represents the result of Student t test. 
 
3.6 Pi3k/Akt inhibitor LY294002 attenuates mast cell induced tumor 
proliferation and invasion 
3.6.1 Pi3k/Akt inhibitor LY294002 inhibits mouse MC degranulation 
In vitro assays were performed to validate inhibition of degranulation of the gut 
derived primary mouse mast cells by LY294002. The ß-hexososaminidase 
release (%) in carrier-treated GMMCs (33.75 ± 0.49) dropped after 5 µM 
LY294002 (11.28 ± 0.47, *P<0.05) and 10 µM LY294002 (6.86 ± 0.39, *P<0.05, 
Figure 25) treatment.  
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Figure 25. LY294002 attenuates in vitro murine primary mast cell 
degranulation in IL-10-/- mice. Figure depicts quantitation of % in vitro β-
hexosaminidase release from GMMCs after treatment of carrier or 5 µM 
or 10 µM LY294002. * P < 0.05 represents the result of Student t test. 
Next, pretreated conditioned medium (with 10 µM LY294002 or carrier) obtained 
from mouse mast cells to study the effect of PI3K inhibition on mouse MCs in 
context with CT44 mouse colon cancer proliferation and invasion. 	  
3.6.2 Pi3k/Akt inhibitor LY294002 attenuates the rate of mouse MC induced 
CT44 proliferation 
LY294002 pretreated conditioned medium significantly attenuated the mean 
CT44 cell proliferation counts (8580.00 ± 1009) in comparison to conditioned 
medium obtained from carrier-treated mouse MCs at 24 hours time points 
(12910.00 ± 678.20, *P<0.05, Figure 26). However, at 48 and 72 hours time 
points there was no significant difference between the two groups (data not 
shown). 	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Figure 26. LY294002 attenuates in vitro murine mast cell associated 
CT44 tumor cell proliferation. Figure depicts quantitation of mean ± 
standard error CT44 mouse colon cancer proliferation at 24 hour time 
point in response to carrier or 10 µM LY294002 treated GMMC 
conditioned medium. * P < 0.05 represents the result of Student t test. 
3.6.3 Pi3k/akt inhibitor LY294002 attenuates mouse MC induced CT44 
invasion 
Similarly, the mean CT44 cell invasion/well after normalization (CT44 invasion 
count number in carrier-treated study group only was normalized by reducing 
33.53% since at 24 hours the CT44 proliferation was attenuated by 33.53%) was 
significantly attenuated by 10 µM LY294002 pretreated conditioned medium 
(303.70 ± 16.70) in comparison with conditioned medium from carried-pretreated 
mouse mast cells (516.70 ± 45.18, *P<0.05, Figure 27A and 27B).  
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Figure 27. LY294002 attenuates in vitro murine mast cell associated 
CT44 tumor cell invasion. (A) Representative images of CT44 mouse 
colon cancer cell invasion in response to conditioned medium obtained 
either carrier or LY294002 treated GMMCs. (B) Quantification of mean ± 
standard error CT44 cell invasion/well in response to carrier or 10 µM 
LY294002 treated GMMC conditioned medium. * P < 0.05 represents the 
result of Student t test. 
These observations show that PI3K and phosphorylation of AKT are critical for 
mast cell functions that promote cancer and LY294002 inhibits the cancer 
promotion by inhibiting these properties. 
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4.	  Discussions	  
 
It has been known for long that inflammation plays an important role in cancer 
development. Ulcerative colitis patients with prolonged chronic inflammation are 
at high risk to develop invasive colon cancer. PI3K pathway has been a subject 
of interest in cancer development for researchers globally, however less is known 
about the role played by PI3K/AKT in the inflammatory component for the tumor 
development. The over-all aim of this project was to study the change in the 
pattern of PI3K/AKT and inflammation as disease progress from colitis to cancer, 
followed by a detailed investigation of the role of PI3K/AKT in inflammation and 
whether PI3K/AKT in inflammation regulate the tumor progression and cancer 
development using human patient specimens, in vitro assays and in vivo 
experimental colitis associated cancer mouse model system.  
 
4.1 Selection and characterization of patients based on histopathological 
study 
 
Inflammation plays a pivotal role in initiation and progression of colon cancer 
(Khazaie et al, 2011; Terzic et al, 2010). Chronic inflammation in UC patients 
increases the risk of rapidly progressing CRC (Allavena et al, 2008; Bargen & 
Gage, 1960; Bouma & Strober, 2003; Cho et al, 2008; Crivellato et al, 2008; 
Dostert et al, 2008; Ekbom et al, 1990; Gounaris et al, 2008; Gupta et al, 2007; 
Gyde et al, 1988; Itzkowitz & Yio, 2004; Karlen et al, 1999; Kobayashi et al, 
2006; Lakatos & Lakatos, 2008; Lemmon, 2008; Ransohoff, 1988; Taskinen et al, 
2008; Ullman, 2003; Yodavudh et al, 2008a; Yodavudh et al, 2008b). Hence, 
based on histopathological study patient specimens were chosen and grouped 
into 4 categories i.e. normal, colitis, dysplasia and cancer. The objective here 
was to study the immunopathological changes happening in the colon, when the 
disease is progressing from normal to colitis, dysplasia and cancer. Previous 
studies in colitis have majorly been restricted to either comparison between 
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normal versus colitis, or colitis versus colitis associated cancer (Coussens et al, 
1999; Imada et al, 2000; Johansson et al, 2010; Nonomura et al, 2007; Ribatti et 
al, 2000; Ribatti et al, 2003; Takanami et al, 2000; Terada & Matsunaga, 2000; 
Toth-Jakatics et al, 2000). For the first time a novel study pattern was decided 
where the pathological and immunological studies were correlated and studied 
from normal to inflammation-associated cancer development. 
4.1.1 PI3K in human colonic specimen study 
It is known that PI3K activity significantly rises in CRC and is associated with 
poor prognosis (Philp et al, 2001; Velho et al, 2005). Mouse models of UC have 
shown that PI3K activity is critical for progression to cancer (Brown et al, 2010; 
Gounaris et al, 2007; Jain et al, 2010; Kim et al, 2010; Lee et al, 2010; Nigrovic 
et al, 2010; Strouch et al, 2010). However, much of what is known is focused on 
the role of PI3K signaling in tumor cells; furthermore, the relevance to 
inflammation driven colon cancer in humans remains unclear (Brown et al, 2010; 
Cook et al, 2010; Gounaris et al, 2007; Jain et al, 2010; Kim et al, 2010; Lee et 
al, 2010; Nigrovic et al, 2010; Strouch et al, 2010).  
Hence, pAKT levels were studied using immunohistochemical staining and were 
differentially characterized at histological sites of mucosa (epithelial vs. stromal) 
and submucosa in a novel investigation of chronic inflammation associated 
colonic dysplasia and invasive cancer. By in situ staining of human surgical 
specimens, the first evidence found was that PI3K/AKT activity is found 
predominantly in the stromal infiltrates and submucosal inflammatory cells in 
comparison with the epithelium. Moreover, the mucosal pAKT levels did not 
change with the progression of disease from colitis to dysplasia and cancer. 
However, the submucosal pAKT levels increased progressively from normal to 
colitis, dysplasia and cancer. Hence, next step was to investigate what subsets of 
inflammatory cell population display PI3K/pAKT.  pAKT activity overlapped 
abundantly with CD68+ macrophages and tumor infiltrating inflammatory cells. 
These CD68+pAKT+ macrophage cell population showed identical pattern of 
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infiltration as total pAKT cells. They progressively rose in the submucosal areas 
from normal to colitis, dysplasia and cancer. These observations are indicative of 
production of macrophage-chemotactic factors in the submucosal area of active 
inflammation. These macrophages are recruited in the submucosal area and with 
them they bring in high pAKT activity incrementally in the colitis, dysplastic and 
invasive cancer submucosal area. Progressive rise of pAKT+ macrophages in the 
submucosal area with peak levels in the invasive cancer is indicative of highest 
levels of macrophage chemotactic factors being produced by the submucosa of 
invasive colon cancer. In a similar study of murine model for breast cancer, 
macrophages were recruited by the tumor cell-derived chemokine CCL5. When 
treated with the receptor antagonist met-CCL5, both the number of infiltrating 
macrophages and the size of the tumor were significantly reduced(Robinson et 
al, 2003). Moreover, TAMs are differentiated from monocytes via number of 
chemoattractants that are produced by tumor and stromal cells. For instance, 
tumor-derived chemokine CCL2, previously known as monocyte chemotactic 
protein (MCP), is critical for the recruitment of macrophages(Coussens & Werb, 
2002; Graves et al, 1989). Tumor cells, fibroblasts, and macrophages produce 
CCL2, and high CCL2 levels are correlated with increased numbers of TAMs and 
a poor cancer prognosis (Siveen & Kuttan, 2009). Other chemokines, such as 
CCL3, CCL4, CCL5, CCL7, CCL8, CXCL12, and cytokines, including vascular 
endothelial growth factor (VEGF), IL-10 and, platelet-derived growth factor 
(PDGF) are also reported to promote macrophage recruitment (Allavena et al, 
2008; Balkwill & Coussens, 2004; Murdoch et al, 2004; Solinas et al, 2009). In 
addition, another group of monocyte chemoattractants, called the alarmins, have 
been reported to promote the recruitment of monocytes and other myeloid 
cells(Coffelt & Scandurro, 2008). For example, the high mobility group box 
protein 1 (HMGB1), which is one of the molecules released by dying or apoptotic 
tumor cells, is found in the necrotic areas where TAMs preferentially reside. 
Other alarmins, such as S100A8, S100A9, serumamyloid A3 (SAA3), and 
fibronectin, have also been reported to attract CD11b+ myeloid origin cells(Coffelt 
et al, 2009). In total, it can be concluded that macrophages are driven to the area 
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of active inflammation, predominantly at submucosa of colon where an array of 
macrophage chemotactic factors are produced. 
4.1.2 Mast cells in human colonic specimen study 
 
In addition to tumor cells, MC the sentinel cells have been known to produce 
huge array of chemottractants for macrophages(Cheon et al, 2011; Crivellato et 
al, 2008; Khazaie et al, 2011; Maltby et al, 2009). Hence, the presence of MC in 
the patient tissue specimens was investigated. MC frequencies were found in 
identical pattern with pAKT and CD68+ macrophages. MC were found 
predominantly in the submucosa in a progressive pattern from normal to colitis, 
dysplasia and cancer. These results are in accordance with numerous 
observations and findings that report the increase in MC frequencies in 
cancer(Cheon et al, 2011; Crivellato et al, 2008; Khazaie et al, 2011; Maltby et al, 
2009), but this study for the first time report the spatial distribution of MC in the 
mucosal and submucosal areas, where other study have not been accurate to 
point the area of predilection for inflammation and pAKT.  Hence from above it 
can be understood that mast cells may recruit macrophages in the submucosal 
tumor microenvironment. 
4.2 Mast cells recruit macrophages and promote tumor proliferation and 
invasion in PI3K/AKT dependent manner 
4.2.1 PI3K/AKT in mast cells recruit macrophage migration 
MC are found predominantly in submucosa of cancer in this study; are sentinel 
cells that proliferate on activation at the site of inflammation and are known to 
recruit macrophages(Cheon et al, 2011; Crivellato et al, 2008; Khazaie et al, 
2011; Maltby et al, 2009), moreover PI3K is essential for the survival and 
biological functions of MC (Kim et al, 2008c), hence investigation was performed 
if MC associated macrophages recruitment is PI3K dependent? Conditioned 
medium obtained from MC promoted migration of healthy peripheral blood 
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derived macrophages. Next, addition of LY294002 to the conditioned medium 
attenuated macrophage migration. Moreover, the macrophage migration was 
attenuated significantly even further when the conditioned medium obtained after 
LY294002 pre-treated MC was used. These observations are first evidence for 
the role of PI3K/AKT signaling in the biology of MC in context with tumor 
promoting properties. Moreover, the soluble factors from MC are released in the 
tumor microenvironment in a PI3K dependent manner that recruits the 
macrophages and PI3K/AKT activity to the tumor. Addition of LY294002 to the 
conditioned medium has a direct effect on macrophage migration. Similar 
observations were reported for mouse and human macrophage migration using 
LY294002 (Baek et al, 2001). Moreover, soluble factors released by MC were 
tightly regulated by PI3K/AKT and blocking PI3K/AKT in MC attenuates the 
macrophage migration to the highest degree. Thus immunohistochemical-based 
spatial distribution study for pAKT, macrophages and MC was critical in 
understanding that MC might be at the central-axis of macrophage and PI3K/AKT 
recruitment to the tumor microenvironment and predominantly in the sub-
musoca, which is the site of crypt-invasion in invasive cancers. Moreover, these 
in vitro studies results were pivotal in understanding that PI3K upregulation seen 
in colitis-associated invasive colon cancer is attributed to the macrophages and 
the tumor infiltrating leukocytes that are recruited predominantly in the colonic 
submucosa. 
4.2.2 PI3K/AKT in mast cells regulate mast cell degranulation 
Mast cells release various factors by secretion and degranulation in the tumor 
microenvironment(Khazaie et al, 2011; Maltby et al, 2009). In addition to 
secretion PI3K regulates the degranulation of MC(Kim et al, 2008b). A dose-
dependent inhibition of the release of β-hexosaminidase (degranulation) was 
observed in the MC that were treated with LY294002. These observations are in 
agreement with various studies that have investigated the role of PI3K in mast 
cell biology(Kim et al, 2008b; Lam et al, 2008). The PI3K inhibitors, Wortmannin 
and LY294002, have been widely reported to inhibit antigen-mediated 
105	  	  
degranulation and cytokine production in both human and rodent mast cells (Kim 
et al, 2008a; Okayama et al, 2003; Tkaczyk et al, 2003). Studies utilizing mouse 
bone marrow-derived mast cells (BMMCs) expressing a kinase-inactive mutant 
isoform of the p110δ catalytic subunit have shown that p110δ is the major 
isoform responsible for antigen-mediated degranulation and cytokine production 
in MC(Ali et al, 2004; Ali et al, 2008). This observation is further supported by the 
ability of the selective p110δ inhibitor, IC87114, to inhibit antigen-mediated MC 
activation and by its ability to inhibit the enhancement of antigen-mediated 
degranulation by stem cell factor (SCF)(Ali et al, 2004). By contrast, MC derived 
from the bone marrow of p85α and p85β knock out mice show normal antigen-
mediated calcium flux and degranulation(Lu-Kuo et al, 2000; Tkaczyk et al, 
2003), suggesting that the p110 catalytic subunit can utilize alternative regulatory 
subunits for its interaction with phosphorylated Gab2(Kim et al, 2008c) . 
4.2.3 PI3K/AKT in mast cells promote tumor proliferation 
MC are known to produce various growth factors and array of tumor promoting 
cytokines, chemokines and proteases that plays an vital role in tumor 
promotion(Maltby et al, 2009). MC release these growth factors in a PI3K/AKT 
dependent manner, hence the role of PI3K in MC dependent tumor proliferation 
and invasion was studied. MC conditioned medium that possess the soluble 
growth factors released by MC (Cheon et al, 2011; Strouch et al, 2010), when co-
cultured with tumor cells promoted ex vivo tumor proliferation at 24, 48 and 72 
hour time points. Whereas, when LY294002 was added to this conditioned 
medium for co-culture the rate of tumor proliferation was restricted. However, 
when LY294002 pre-treated MC conditioned medium was co-cultured with tumor 
cells, the rate of tumor proliferation was further significantly attenuated. These 
findings suggest that tumor proliferation was promoted via soluble factors 
released from MC that are regulated by PI3K. Moreover, reduction in the tumor 
proliferation rate by addition of LY294002 to the MC conditioned medium 
indicates that LY294002 targets the PI3K in the tumor cells directly and restricts 
their proliferation in the presence of active MC soluble factors. Finally, the 
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highest attenuation of tumor proliferation achieved with co-culture of LY294002 
pre-treated MC conditioned medium indicates that PI3K/AKT in MC regulate the 
release of MC soluble factors that promote tumor growth. In addition, this 
blockage of MC soluble factor release is very potent and strongly attenuates the 
tumor proliferation in comparison with the study group where LY294002 is added 
to the MC (non LY294002 pre-treated) conditioned medium for coculture with 
tumor cells, which could be attributable to the absence of any active MC soluble 
tumor-promoting growth factors in the former group. Similar observations were 
reported with MC conditioned medium induced tumor proliferation in pancreatic 
cells lines Panc-1, HPDE and AsPC1(Strouch et al, 2010), where increase in 
pancreatic cell proliferation was found using LAD-2 MC conditioned medium by 
all three cell lines at 24, 48 and 72 hours time points in comparison with non-
conditioned medium. Furthermore, in agreement to these observations another 
study demonstrated that APCΔ468 and wild type mouse MC conditioned medium 
promoted in vitro colonic epithelial proliferation incrementally at 24 hours, 48 
hours and 72 hours time point(Cheon et al, 2011). In a similar study aimed to 
investigate direct effect of LY294002 on cancer cells, LY294002 was found to be 
effective in vitro against a range of colon cancer cell lines including HT-29 and 
COLO-320 (Garman et al, 2008). Moreover, the tumor recurrence was 
significantly affected after LY294002 treatment (Garman et al, 2008). In another 
in vitro study LY294002 alone did not produce cytotoxic effects, however PI3K 
inhibition with LY294002 significantly radiosensitized the cervical cancer cells 
and showed significant time-dependent effects, increased apoptosis, and altered 
gene expression (Lee et al, 2006). In this study by Lee et al, no effect of 
LY294002 on tumor proliferation could be attributable to the different cancer 
lineages and acquired secondary mutations in the cervical cancer cell lines. 
However, in another study mixed results were seen on tumor growth using 
LY294002.  In this study, LY294002 demonstrated a remarkable growth-inhibitory 
and apoptosis-inducing effect in these colon cancer cell lines, with reduced 
expression of phosphorylated Akt (Ser473). However, there was a great 
discrepancy in between the sensitivity for LY294002 and the levels of expression 
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of pAKT. Although, the LoVo and Colo205 cells displayed high sensitivity to 
LY294002 with increased apoptosis, the DLD-1 and HCT15 cells did not 
exhibited rapid induction of apoptosis. The caspase-3 activity was significantly 
elevated in the LoVo cells but not in the DLD-1 cells. In the in vivo experiments 
using mouse xenografts, LY294002 administration was found effective in the 
suppression of tumor growth and induction of apoptosis, especially in the LoVo 
tumors, and therefore showed striking effectiveness in the mouse peritonitis 
carcinomatosa model. 
4.2.4 PI3K/AKT in mast cells promote tumor invasion 
In addition to tumor proliferation, tumor invasion is an important phenotype 
displayed by tumors, necessary for subsequent metastases. Tumor invasion and 
metastases constitute is a major problem in the treatment of carcinoma patients. 
About 30% of cancer patients with newly diagnosed solid tumors already have 
clinically detectable metastases. A metastatic colony is the result of a continuous 
process starting from the early growth of the primary tumor, and detachment of 
invasive tumor cells from the primary tumor leading to the colonization of other 
organs (Fidler et al. 1978, Fidler & Hart 1982, Weiss 1985, Fidler & Balch 1987). 
Tumor cell invasion is a complex process that involves genetic and cellular 
alterations leading to proteolysis and dispersion through three-dimensional 
biological barriers(Friedl & Wolf, 2003; Gehlsen et al, 1992; Mignatti & Rifkin, 
1993; Stetler-Stevenson et al, 1993). Extracellular matrix (ECM) including the 
type I collagen, which is the most abundant component of the extracellular matrix 
(ECM) forms a significant barrier for tumor cell dissemination into the lymphatics, 
vasculature, and surrounding areas(Sabeh et al, 2004; Seiki, 2003). Thus, in 
most cases, collagen and ECM must be degraded in order for tumor cells to 
spread into surrounding anatomic structures and metastasize(Chambers et al, 
2002). Cell migration, regulated by polarity and reorganization of the cellular 
cytoskeleton, is also an integral aspect of tumor cell invasion(Hanahan & 
Weinberg, 2000; Ridley et al, 2003). Dissecting the etiological factors governing 
the tumor cell migration and invasion is necessary because the latter, in 
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conjunction with metastasis, is a significant cause of morbidity and mortality in 
cancer patients (Sporn, 1996).  
Matrigel is the trade name for a gelatinous protein mixture secreted by 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, which resembles the 
complex extracellular environment and ECM found in many tissues(Benton et al, 
2009; Hughes et al, 2010). Mast cells are rich source of metalloproteases that 
contribute the majority of proteolytic components necessary to break the ECM for 
tumor invasiveness(Cassano et al, 2006; Theoharides & Conti, 2004).  Mast cells 
can disturb normal stromal-epithelial communication and degrade matrix at sites 
of tumor invasion. Mast cells also generate and secrete IL-8, which can act as an 
angiogenic factor, as well as a tumor cell chemotactic factor and tumor 
mitogen(Moller et al, 1993). In fact, blocking of IL-8 by use of neutralizing 
antibodies reduces human non-small cell lung carcinoma progression in 
mice(Brew et al, 2000).  
Using in vitro experiments with human derived cell lines and MC soluble factors 
containing conditioned medium, studies were performed to investigate the role of 
PI3K in MCs in matrigel based invasion assays. Conditioned medium obtained 
from MCs promoted tumor invasion and migration in comparison with the non-
conditioned medium. Moreover, addition of LY294002 to MC conditioned medium 
attenuated tumor cell invasion. Furthermore, in line with the observations from in 
vitro assays discussed previously, conditioned medium obtained from MC 
pretreated with LY294002 attenuated the tumor invasion to the highest levels. In 
a similar study MC conditioned medium was reported to promote Pancreatic 
cancer cell invasion of Panc-1 and HDPE through the matrigel by upregulation of 
matrix metalloproease- 2 and -9(Strouch et al, 2010).  In another group of study, 
in an attempt to investigate direct effect of PI3K/AKT attenuation via LY294002 
on invasive potential of gastric cancer similar observations were found, where the 
in vitro invasion assay and the in vivo nude mice assay suggested that LY249002 
had the potential to inhibit the invasion and metastasis of gastric cancer(Xing et 
al, 2009). This inhibition could be a result of the decrease in the expression of 
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MMP-2, MMP-9, MVD and VEGF together with the cytotoxicity towards the tumor 
MMP-2, MMP-9, MVD and VEGF together with the cytotoxicity towards the tumor 
cells, both induced by LY294002 (Xing et al, 2009). In another study invasion 
assays were performed with or without LY294002 (10 µM for 48 hours) and a 
reduction in the invasion of melanoma cell line WM35RhoC was observed (Ruth 
et al, 2006). Finally in vitro direct effect of LY294002 on tumor invasion was 
reported extensively in HT1080 human fibrosarcoma cells, MDA-MB-231 breast 
cancer cells and B16F10 melanoma cells(Yoon et al, 2006), furthermore MMP-9 
based mechanism was reported as critical for these tumor invasions (Yoon et al, 
2006). 
4.2.5 PI3K/AKT in tumor infiltrating leukocytes promote tumor invasion 
In addition to MC, the role of PI3K/AKT in tumor infiltrating leukocytes (TILs) 
were investigated for in vitro matrigel based colon cancer invasion. Once the 
tumor is vascularized, it is infiltrated by leukocytes, a phenomenon seen in all 
solid cancers. The first observation of TILs was done by Rudolf Virchow in 1863 
(Dirkx et al, 2006)and was thought to be the result of chronic inflammation, which 
was already present before tumor development. However, now it is known that 
the presence of leukocytes is a consequence of an immune reaction to the tumor 
itself- first, innate, and later, specific immunity- as the immune system is able to 
recognize tumor-associated antigens(Brigati et al, 2002). In cancer patients, 
specific cytotoxic T lymphocytes recognizing tumor antigens have been reported, 
and the presence of these cells is associated with better prognosis. In addition, 
antibodies to tumor-associated antigens produced by B cells may also play a 
critical role in limiting tumor growth(Scanlan et al, 2001; Vaughan et al, 2004). 
Leukocyte infiltration in tumors is, therefore, often associated with better 
prognosis and overall better patient survival. However, the role of TILs in cancer 
progression and metastasis has been debated frequently. Although often 
considered to be associated with improved prognosis and leading to the 
enhanced survival in cancer patients, inflammatory cells have also been reported 
to assist the tumor’s capabilities to progress, proliferate, and metastasize. 
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Tumor-associated macrophages (TAMs), for instance, have been shown to be 
symbiotically related to tumor cells: Tumor cells recruit TAMs and provide them 
with survival factors, and TAMs in turn produce a variety of angiogenic factors in 
response to the tumor microenvironment(Allavena et al, 2008; Solinas et al, 
2009). 
TILs were isolated from the freshly obtained surgical tissues of ulcerative colitis 
associated cancer. TILs were found to be high in pAKT and LY294002 treatment 
attenuated both Ser473 and Thr308 pAKT. In vitro tumor invasion studies were 
performed mimicking the in vivo phenotype as seen in the immunohistochemical 
studies and spatial distribution of the TAMs and pAKT positive inflammatory 
cells. TAMs from UC patients associated cancer patients promoted HT-29 
invasion, either through their secreted soluble factors in the conditioned medium 
(experimental setup-1) or direct cell-cell contact (experimental setup-2). Indeed, 
when these cells were co-cultured invasion was even more pronounced 
(experimental setup-2). However, LY294002 treatment of Tumor Infiltrating 
Leukocytes reduced their ability to promote HT-29 invasion in both setups. In 
experimental setup-1 PI3K/AKT was found critical for the release of tumor 
invasion-promoting soluble factors from TILs. Whereas, in experimental septup-2 
cell-cell contact between TILs and tumor cells promoted tumor invasion and 
PI3K/AKT was vital in TILs for regulating this cell-cell contact with tumor cells for 
subsequent tumor invasion. In agreement with these observations T-cell 
exosomes were found to promote lung cancer cell invasion(Cai et al, 2012), while 
in another study freshly isolated peripheral blood granulocytes and peritoneal 
macrophages promoted tumor invasion of T-47D (human ductal breast 
carcinoma) and SW620 (human colon carcinoma), interestingly when 
granulocytes and macrophages were used together a synergistic effect on tumor 
invasion was seen(Barbera-Guillem et al, 1999). Moreover, macrophages were 
reported to promote tumor cell invasion by producing EGF ligands that stimulate 
tumor cell motility, especially along collagen fibers that macrophages help to 
fabricate. Macrophages also induce the formation of blood new vessels that are 
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sheaved in collagen, and thus, the migration of tumor cells tends to be focused 
toward these newly formed vessels, thereby directing tumor cells to sites of 
intravasation (Pollard, 2008). The latter process in turn is enhanced by 
macrophages that align upon the outside of the blood vessels that are elaborated 
under the influence of macrophages within the malignant areas and provide 
portals of escape for the tumor cells. All of these macrophage-promoted activities 
of increased angiogenesis as well as enhanced tumor cell migration, invasion, 
and intravasation results in increased metastatic capacity of the tumor (Pollard, 
2008). Few attempts have been made to coculture macrophages with the tumor 
cells in in vitro invasion assays and investigate the change in invasive potential of 
the tumor cell. The human breast cancer cell lines MCF-7, SK-BR-3 and the 
benign mammary epithelial cell line hTERT-HME1 were cocultured with 
macrophages(Hagemann et al, 2004). In agreement with results obtained from 
our current study, Hagemann et al, found that coculture enhanced invasiveness 
of the cancer cells on cell-cell contact, while hTERT-HME1, the benign 
counterpart remained non-invasive. Moreover, addition of the broad-spectrum 
matrix metalloprotease (MMP)-inhibitor FN 439, neutralizing MMP-9 or tumor 
necrosis factor-alpha (TNF-a) antibodies reduced invasiveness to basal 
levels(Hagemann et al, 2004). At basal levels, all cell lines produced low 
amounts of MMP-2, -3, -7 and -9, while basal MMP production by macrophages 
was significantly higher. Upon coculture, supernatant levels of MMPs -2, -3, -7 
and -9 increased significantly, paralleled by an increase of MMP-2 activation. Co-
culture of macrophages and hTERT-HME1 did not lead to MMP induction. In the 
cocultures, mRNAs for MMPs and TNF-a were significantly upregulated in 
macrophages, while the mRNA concentrations in the tumor cells remained 
unchanged. In conclusion, cell-cell contact of tumor cells with macrophages 
leads to enhancement in the invasiveness of the malignant cells due to TNF-a 
dependent MMP induction in the macrophages(Hagemann et al, 2004). In an 
extension to this study by Hageman et al, coculture of macrophages with ovarian 
or breast cancer cell lines led to TNF-α-dependent activation of JNK and NF-κB 
pathways in tumor cells, but not in benign immortalized epithelial cells. Tumor 
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cells with upregulation of JNK and NF-κB activity exhibited enhanced 
invasiveness. Blockage of the NF-κB pathway by TNF-α neutralizing Abs, an NF-
κB inhibitor, RNAi to RelA, or overexpression of IκB attenuated tumor cell 
invasiveness(Hagemann et al, 2005). Blockade of JNK also significantly 
restricted invasiveness, but blockade of p38 MAPK or p42 MAPK had no 
effect(Hagemann et al, 2005). Cocultured tumor cells when screened for the 
expression genes associated with inflammation and invasion that also contained 
an AP-1 and NF-κB binding site, EMMPRIN and MIF were found to be 
upregulated in cocultured tumor cells in a JNK- and NF-κB-dependent 
manner(Hagemann et al, 2005). Knocking down either MIF or EMMPRIN by 
RNAi in the tumor cells significantly attenuated tumor cell invasiveness and 
matrix metalloprotease activity in the coculture supernatant. Hence, in conclusion 
TNF-α, via NF-κB, and JNK induces MIF and EMMPRIN in macrophage to tumor 
cell cell-cell contact cocultures, leading to increase in the invasive potential of the 
tumor cells(Hagemann et al, 2005). 
4.3 PI3K/AKT inhibition attenuates in vivo cancer invasion, cancer-
associated inflammation and cancer promoting properties in mouse model 
 
Observations from in vitro studies were tested in the in vivo mouse model 
system. IL-10-/- mice treated with Piroxicam develop experimental colitis 
associated cancer by day 56 and were used to study the effect of LY294002 
treatment/PI3K inhibition on colitis-associated cancer.  In the IL10 deficient 
mouse model PI3K is required for induction of colitis, and its targeted genetic 
ablation (Brown et al, 2010; Cook et al, 2010; Gonzalez-Garcia et al, 2010; 
Gounaris et al, 2007; Jain et al, 2010; Kim et al, 2010; Lee et al, 2010; Nigrovic 
et al, 2010) or treatment of mice with the broad PI3K inhibitors Mesalamine 
(Brown et al, 2010) or  LY294002 (Brown et al, 2010; Cook et al, 2010; Gounaris 
et al, 2007; Jain et al, 2010; Kim et al, 2010; Lee et al, 2010; Nigrovic et al, 2010) 
protect against colitis. PI3K was described to mediate proliferation and activation 
of Akt resulting in Crypt architectural changes that predispose to colitis (Brown et 
al, 2010; Cook et al, 2010; Gounaris et al, 2007; Jain et al, 2010; Kim et al, 2010; 
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Lee et al, 2010; Nigrovic et al, 2010).  However, as described above using in situ 
staining of human colonic tissue sections that the relative frequency of detectable 
PI3K active cells in the stroma and submucosa is more than 10 fold above that in 
of epithelial cells and increases with colitis and cancer; by contrast, in the IL10-/- 
mouse colon this ratio is reversed. This difference between human and mouse 
tissue may have masked the significance of PI3K activity by tissue infiltrating 
cells in predisposition to colitis and progression to cancer. IL-10-/- that receives 
Piroxicam develops colitis followed by invasive lesions by day 56, however 
simultaneous LY294002 treatment attenuated the development of invasive lesion 
counts. Treatment of LY294002 inhibited epithelial and stromal pAkt counts, 
however LY294002 showed a striking attenuation of stromal pAkt in comparison 
with epithelial pAkt, reduction in the inflammatory scores with LY294002 
treatment could be partially responsible for this observation. Moreover, epithelial 
proliferation was reduced and tumor apoptosis was increased with LY294002 
treatment, which could be well correlated with the reduction in the invasive lesion 
counts. Furthermore, LY294002 treatment reduced granulocyte and mast cell 
frequencies and in situ mast cell degranulation.  In agreement with these 
observations in a similar experimental setup in another study, LY294002 
treatment reduced the frequency of dysplastic lesions, reduced epithelial 
proliferation, epithelial Akt and increased apoptosis (Lee et al, 2006). The critical 
role of phosphoinositide 3-kinase-γ (PI3Kγ) in inflammatory cell activation and 
recruitment makes it an attractive target for immunomodulatory therapy. A study 
with 5-Quinoxilin- 6-methylene-1,3-thiazolidine-2,4-dione (AS605240), a potent 
PI3K inhibitor, has been reported to ameliorate chronic inflammatory disorders 
including rheumatoid arthritis, systemic lupus erythematosus, and atherosclerosis 
and colitis(Peng et al, 2010). In this study therapeutic potential of AS605240 in 
mice with dextran sodium sulfate (DSS)- induced acute and chronic colitis were 
studied. AS605240 improved survival rate, disease activity index, and histological 
damage score in mice administered DSS in both preventive and therapeutic 
studies. AS605240 treatment also significantly inhibited the increase in 
myeloperoxidase levels, macrophage infiltration, and CD4 T-cell number in the 
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colon of DSS-fed mice (Peng et al, 2010). The DSS induced overproduction of 
colonic proinflammatory cytokines including interleukin (IL)-1β, tumor necrosis 
factor-α, and interferon-γ was significantly suppressed in mice undergoing 
AS605240 therapy, whereas colonic anti-inflammatory cytokines such as IL-4 
were up-regulated(Peng et al, 2010). The downregulation of the phospho-Akt 
level in immunological cells from the inflamed colon tissue and spleen of 
AS605240-treated mice was detected both by immunohistochemical analysis and 
Western blotting. These findings demonstrate that AS605240, another PI3K 
inhibitor, may represent a promising novel agent for the treatment of 
inflammatory bowel disease by suppressing leukocyte infiltration as well as by 
immunoregulating the imbalance between proinflammatory and anti-inflammatory 
cytokines (Peng et al, 2010). Another preferential p110α/γ PI3K inhibitor 
(compound 8C; PIK-75) that was found to be effective in inflammation-based 
assays, cell-based assays revealed that PIK-75 potently and dose dependently 
inhibits in vitro and in vivo production of TNF-α and IL-6, diminishes the induced 
expression of human endothelial cell adhesion molecules (E-selectin, ICAM-1, 
and VCAM-1), and blocks human monocyte-endothelial cell adhesion(Dagia et 
al, 2010). Most importantly, PIK-75, when given orally in a therapeutic regimen, 
significantly suppresses the macroscopic and histological abnormalities 
associated with dextran sulfate sodium-induced murine colitis. The efficacy of 
PIK-75 in attenuating experimental inflammation is mediated, at least in part, due 
to the downregulation of pertinent inflammatory mediators in the colon (Dagia et 
al, 2010).  
 
In addition to the investigation performed to dissect the role of PI3K in 
inflammatory cells using human in vitro and mouse in vivo system in cancer 
progression, in vitro role of PI3K in mouse system was performed to confirm and 
crosscheck the observations.  PI3K in gut-derived mouse MC was critical for 
degranulation and mouse colon carcinoma proliferation and invasion. LY294002 
treatment of MC attenuated in vitro degranulation, MC associated mouse colon 
cancer proliferation and invasion.  
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Tissue infiltrating MC and macrophages are sensitive to inhibition of PI3K and 
are abundantly present in increasing numbers during progression to colitis and 
cancer. Therapies that target the PI3K pathway need to take into account that 
tumor cells may not be the primary target cells. These findings demonstrate the 
role of PI3K in tumor infiltrating cells and their communication with tumor cells, 
drawing attention to the role of PI3K signaling in the tissue and tumor 
environment in predisposition to cancer.  	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